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Abstract 
The overall goal of my thesis projects was to characterize the pharmacokinetics, 
bioavailability and tolerability of CNS drugs used in the acute management of seizure 
emergencies and spasticity.  Two drugs were studied: diazepam and baclofen.  Both of 
these drugs are already approved by the FDA and have been extensively used.  For 
diazepam, two novel formulations were evaluated for intranasal delivery as rescue 
therapy in seizure emergencies.  In the case of baclofen, commercially available 
intrathecal baclofen solution was administered intravenously to characterize its 
pharmacokinetics and safety in humans. 
Diazepam rectal gel (Diastat®) is the only FDA-approved product indicated for acute 
repetitive seizures. Despite its proven efficacy, most older children and adults object to this 
route of administration. As a result, many patients do not realize the benefit of a therapy that 
can improve outcomes and decrease healthcare costs. Intranasal administration of 
benzodiazepines offers a potential alternative. The primary objective of this study was to 
compare the bioavailability and pharmacokinetics of two novel intranasal diazepam 
formulations versus intravenous administration in healthy volunteers. Twenty-four healthy 
volunteers were randomized into an open-label, three-way crossover study. Ten mg doses of 
two investigational intranasal diazepam formulations (solution, suspension) and a 5 mg 
intravenous dose of commercially available diazepam injectable, USP were given.  A two-
week washout period separated treatments. Plasma samples for diazepam analysis were 
collected pre-dose and at regular intervals up to 240 hours post-dose. diazepam 
concentration-time data were analyzed using a non-compartmental pharmacokinetics 
approach.  Exposure following administration of diazepam intranasal solution (absolute 
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bioavailability – 97%) was greater than the intranasal suspension (absolute bioavailability- 
67%).  Both investigational intranasal formulations were well tolerated.  The results of this 
pilot study indicate that development of an intranasal diazepam formulation with high 
bioavailability, reasonable variability, and good tolerability is feasible.  Further, a PK model 
was developed and simulation studies were performed to optimize future bioequivalence 
trials.  Absorption characteristics of rectal and nasal diazepam formulations were compared 
using the deconvolution analysis. 
An additional identified problem that this thesis work aims to address is management of 
baclofen withdrawal.  The current recommended management strategies for baclofen 
withdrawal are inadequate and availability of intravenous baclofen would permit rapid 
attainment of drug concentrations in plasma as well as accurate and precise dose titration, 
thus allowing for prevention and expeditious treatment of withdrawal symptoms and reduced 
risk of adverse effects.  The objective was to characterize baclofen pharmacokinetics and 
safety given orally and intravenously.  Twelve healthy subjects were enrolled in a 
randomized, open-label, crossover study and received single doses of baclofen: 3 or 5 mg 
given IV and 5 or 10 mg taken orally with a 48-hr washout. Blood samples for baclofen 
analysis were collected pre-dose and at regular intervals up to 24 hours post-dose. Clinical 
response was assessed by sedation scores, ataxia and nystagmus.  Mean absolute 
bioavailability of oral baclofen was 74%.  Dose-adjusted areas under the curve (AUC) 
between the oral and IV arms were statistically different (p=0.0024), while AUC variability 
was similar (co-efficient of variation: 18-24%). Adverse effects were mild in severity and not 
related to either dose or route of administration.  Three and 5 mg IV doses of baclofen were 
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well tolerated. Seventy-four percent oral bioavailability indicates that smaller doses of IV 
baclofen are needed to attain comparable total drug exposures.  
Both intranasal diazepam and intravenous baclofen hold promise in management of seizure 
emergencies and baclofen withdrawal, respectively.  Results from studies described in this 
thesis will inform the design of subsequent clinical studies that are needed for market 
approval. 
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INTRODUCTION 
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1.1 Epilepsy 
 
Epilepsy is the 4th  most common chronic neurological disorder in United States after 
migraine, stroke and Alzheimer’s disease [1] with episodic manifestations that are 
associated with abnormal electrical discharges in the brain [2].   Approximately 1-2% of 
the global population suffer from epilepsy with estimates from the World Health 
Organization data indicating a prevalence of 50 per 100,000 of the general population [3].   
Nearly 3 million Americans (~1% of US population) have epilepsy, 10% of those 
affected are under the age of 15 (300,000 children) and 25% are above the age of 65 [1].  
Typical seizures in ambulatory patients are self-limited and last less than 3 minutes [4]. 
More than half of patients with a first seizure will go on to have another.  Epilepsy was 
deﬁned conceptually by a task force of the International League Against Epilepsy (ILAE) 
in 2005 as a disorder of the brain characterized by an enduring predisposition to generate 
epileptic seizures. This deﬁnition is usually practically applied as having two unprovoked 
seizures >24 h apart and has some limitations [5]. Therefore, the ILAE commissioned a 
second task force to develop a practical (operational) definition of epilepsy, designed for 
use by doctors and patients and the results of several years of deliberations on this issue 
have been published recently [6]. The second task force proposed that epilepsy be 
considered to be a disease of the brain deﬁned by any of the following conditions: (1) at 
least two unprovoked (or reﬂex) seizures occurring >24 h apart; (2) one unprovoked (or 
reﬂex) seizure and a probability of further seizures similar to the general recurrence risk 
(at least 60%) after two unprovoked seizures, occurring over the next 10 years; (3) 
diagnosis of an epilepsy syndrome.   
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Approximately 30-40% of patients who have achieved seizure control with the use of 
antiepileptic drugs (AEDs) experience breakthrough seizures due to non-adherence to 
AEDs, infection/fever, severe stress, sleep deprivation, and metabolic or hormonal 
events/changes [2]. Moreover, these breakthrough seizures often result in seizure 
emergencies. Adequate and effective treatment in a timely fashion is critical to the 
successful management of patients encountering seizure emergencies. 
1.1.1 Seizure Emergencies 
 
Seizure emergencies, while not well-defined, include a wide spectrum of seizures 
including acute repetitive seizures, prolonged episodes lasting many minutes, and status 
epilepticus (SE) [7].  Acute seizures are the most common emergency related to epilepsy 
and account for about one million emergency department (ED) visits a year, or 1% of all 
ED visits in the US [8].  The worldwide annual incidence of acute seizures ranges from 
70 to 100 in 100,000 [9]. The annual cost of prehospital and ED care alone has been 
estimated at $1 billion in the US [10].  Often identification of acute seizures occurs by 
observation of motor symptoms such as clonic jerking, known as convulsive seizures.  
However, it is to be noted that the majority of seizures in adults do not have prominent 
motor activity and are typically referred to as nonconvulsive seizures. Seizures which are 
prolonged (30 minutes) or recurrent without a return to baseline are referred to as SE 
(Figure 1).   
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Figure 1: Evolution of Severe Seizures [11] 
 
SE cause an estimated 42,000 deaths each year with a case-fatality rate ranging from 15% 
to 22% [12].  Mortality in acute symptomatic SE is up to 34% and is between 38-67% in 
the elderly [13] .  SE can cause serious neuronal damage; it has been shown in an animal 
model that even if the systemic effects of SE are controlled, 30 minutes of SE may cause 
significant histologic damage [14] and thus treatment that is initiated early is much more 
likely to improve outcomes.  Although early treatment leads to better outcomes [15], an 
examination of database of patients admitted in the greater Richmond, Virginia area 
between 1989– 1994 revealed that approximately 60% of patients receive treatment after 
a delay of more than 30 minutes [16].  Many neurologists use an operational definition of 
SE as any seizure lasting more than 5 minutes, or 2 or more seizures between which there 
is incomplete recovery of consciousness to enable timely and effective treatment [17].   
1.1.1.1 Acute Repetitive Seizures (ARS) 
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Acute repetitive seizures are a predictable component of a patient’s seizure disorder, 
historically distinct from other epileptic seizures in type, frequency, duration, or severity 
and with an onset easily recognized by the caregiver and physician [18].  Approximately 
80% of seizures are spontaneous and unpredictable.  Although rare, seizures may be 
provoked by specific precipitating events (~1%) [18].  The rest of the approximately 19% 
of seizures have a cyclical pattern recurring at more or less foreseeable intervals of days 
to weeks but with high variability from patient to patient.  Although several terms such as 
serial, repetitive, recurrent, cluster or crescendo seizures have been used in literature to 
describe this cyclical pattern of seizures, none has ever constituted a standardized 
definition.   
 
In the mid-1990s, the emergence of rectal diazepam product for treatment of these 
cyclical pattern seizures led the US Food and Drug Administration (FDA) to define for 
labeling purposes, the entity for which patients could be safely and effectively treated.  
The National Institute of Health Epilepsy Advisory Committee defined acute repetitive 
seizures as a characteristic episode of multiple seizures within 24 hours for adults (12 
hours for children) despite optimal therapy and is recognizable by the patient’s caregiver 
and distinguishable from other seizures.  Upon FDA’s recommendation, a nine-member 
panel of epilepsy experts in 1995 signed an affidavit describing acute repetitive seizures 
as a “…recognized chronobiological entity that can be defined as a form of seizures that  
1) are severe 
2) are a predictable component of the patient’s seizure disorder 
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3) are historically distinct from the patient’s other seizures in type, frequency, 
severity, or duration 
4) have an onset that is easily recognized by the family and physician 
5) demonstrate patient recovery between seizures 
6) have a consistent component (such as an aura, prodrome, or characteristic single 
or multiple seizures) that is predictably and temporally linked to subsequent 
seizures, and 
7) are a constellation of seizures variously referred to as recurrent serial, cluster, or 
crescendo seizures” (Peripheral and Central Nervous System Drugs Advisory 
Committee Meeting # 45; November 15, 1996). 
1.1.2 Available Modes of Treatment and Unmet Need 
 
Rescue therapy such as rectal diazepam is given as needed in an attempt to disrupt 
progression of a given seizure, and forestall what would otherwise be a more prolonged 
or more severe clinical event i.e. status epilepticus [7].  Treatment of seizure emergencies 
commonly involves intravenous administration of benzodiazepines (lorazepam or 
diazepam) and/or other antiepileptic drugs such as phenytoin, valproic acid, and 
levetiracetam by medical personnel [19].   The Neurocritical Care Society recommends 
use of intravenous (IV) lorazepam for treatment of status epilepticus when skilled health 
care personnel are available [20].  In a recent randomized trial in pediatric patients with 
convulsive status epilepticus, treatment with lorazepam did not result in improved 
efficacy or safety compared with diazepam [21].  Chamberlain et al [21] recommended 
that either diazepam, lorazepam, or midazolam could be chosen as a reasonable 
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first-line therapy. Although the IV route is the most effective option for quick cessation of 
seizures, therapy is often delayed when skilled medical personnel and transportation to 
medical facility is required for drug administration.  A retrospective medical review of 30 
patient records admitted to the ED revealed that the average total time from onset of seizures 
to treatment was 85 minutes [22] (Table 1).  Studies have also shown that prolonged or 
repetitive seizures can produce morphological cortical brain damage [23] and the efficacy of 
routinely used benzodiazepines for treatment of such seizures decreases as the duration of 
seizures increases [24].  Due to this delay in therapy and resulting brain damage from 
untreated seizures, there is a great need for safe and effective rescue therapies which are 
quick and easy to administer as well as socially acceptable. 
 
Table 1. Average Time for Events Taking Place in a Patient Experiencing Seizure 
Emergency 
From To Average time to event (range) 
Onset of seizures  Arrival of the emergency 
medical technician (EMT) 
30 minutes (15-140 minutes) 
Arrival of the EMT Arrival of patient at the ER 20 minutes (10-40 minutes) 
Arrival of patient at the ER Initiation of a seizure 
treatment protocol 
35 minutes (15-83 minutes) 
Onset of seizures Treatment of seizures 85 minutes 
 
 
In 1997, rectal diazepam gel, Diastat® was approved by the FDA for the management of 
selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs 
(AEDs), who require intermittent use of diazepam to control bouts of increased seizure 
activity.  Two well-controlled clinical trials have shown that rectal diazepam is safe and 
effective in treating acute repetitive seizures.  Despite the proven efficacy of diazepam 
rectal gel, many older children and adult patients object to this route of administration 
due to privacy, legal, and social concerns [25].  Because of these concerns, there 
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continues to be an unmet need for an alternate route of administration that is not only safe 
and effective, but also acceptable by patients, families and providers. 
1.1.3 Benzodiazepines for Seizure Emergencies 
 
For management of seizure emergencies, a drug should: have a wide therapeutic index; 
be sufficiently potent so as to permit use in small volumes; lend itself to methods of 
administration that are quick, easy, and safe; have a rapid onset of action (minutes) and 
an intermediate duration of action (hours) [26].  Benzodiazepines (BZDs) meet many of 
these criteria and are considered the drugs of choice for treating seizure emergencies as 
rescue therapy [26].  
1.1.3.1 Mechanism of Action of Benzodiazepines   
 
All BZDs have the same mechanism of action i.e., binding to the gamma amino butyric acid 
type A (GABAA) receptors.  Their binding to gamma subunit of GABAA receptors causes an 
allosteric (structural) modification of the receptor, which results in an increase in GABAA 
receptor activity. BZDs do not substitute for GABA, which bind at the alpha subunit, but 
increase the frequency of channel opening events which leads to an increase in chloride ion 
conductance resulting in hyperpolarization of the neuron. This causes an inhibitory effect on 
neurotransmission by diminishing the chance of occurrence of a successful action potential 
(Figure 2).   
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Figure 2: Mechanism of Action of Benzodiazepines [27] 
 
This enhanced effect of the neuroinhibitory transmitter, GABA, at the GABAA receptor 
results in sedative, hypnotic, anxiolytic, anticonvulsant, muscle relaxant, and amnesic 
actions, which are useful in a variety of indications such as alcohol dependence, seizures, 
anxiety, panic, agitation, and insomnia. In general, benzodiazepines are well-tolerated 
and are safe and effective drugs in the short term for a wide range of conditions. 
Tolerance can develop to their effects and there is also a risk of dependence, and upon 
discontinuation a withdrawal syndrome may occur. These factors, combined with other 
possible secondary effects after prolonged use such as psychomotor, cognitive, or 
memory impairments, limit their long-term applicability. The effects of long-term use or 
misuse include the tendency to cause or worsen cognitive deficits, depression, and 
anxiety. 
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1.1.3.2 General Consideration Affecting Choice of Drug  
 
While the mechanism of action is same for all BZDs, there are significant differences in 
physico-chemical properties and pharmacokinetic (PK) characteristics, which affect the 
choice of drug and route of administration.  Below is a brief discussion of physico-chemical 
and PK differences of three benzodiazepines commonly used in the management of 
seizure emergencies and their impact on selection of drug and route of administration for 
treating seizure emergencies. 
1.1.3.2.1.  Lipid Solubility Considerations 
 
An important physico-chemical property affecting the absorption and distribution of a 
drug is its lipid solubility.  The greater a drug’s lipid solubility, the faster is its absorption 
across membranes including rectal, muscular, buccal, nasal tissues as well as the blood-
brain-barrier.  Diazepam and midazolam are 4 and 6 times more lipid soluble than 
lorazepam (see Partition Ratio, Table 2). With respect to midazolam, the commercial 
injectable formulation is buffered to a pH of 3 that produces an ionized open ring 
compound with good water solubility. Following administration, as midazolam 
encounters physiologic pH, the open ring closes resulting in a highly lipid soluble 
structure.  When given IV, diazepam, lorazepam, and midazolam enter the central nervous 
system (CNS) within a few minutes with a corresponding fast onset of effect.  However, 
lorazepam redistributes out of the CNS into muscle and fat tissue more slowly resulting in a 
longer duration of effect.  This property makes lorazepam the drug of choice to treat seizure 
emergencies when given IV. 
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When treating a seizure emergency by an extravascular route, the differences in lipid 
solubility and pharmacokinetics result in a different choice of benzodiazepines.   Diazepam 
and midazolam when given extravascularly display significantly faster rates of absorption 
than lorazepam due to their high lipid solubility and re-distribution to muscle and fat tissues 
is not as pronounced.  Consequently, diazepam and midazolam are preferred when non-IV 
routes are indicated, but their performance will vary by formulation, route of 
administration and type of seizure emergency.  
 
Table 2. Physico-chemical Properties and Pharmacokinetic Parameters of 
Diazepam, Midazolam and Lorazepam 
Drug Molecular 
Weight[28] 
Partition 
Ratio[28] 
Oral 
Bioavailability[29] 
(%) 
Protein 
Binding[29] 
(% bound) 
Elimination 
Half-life[29] 
(hours) * 
Diazepam 309 309 100 96-99 21-70 
Lorazepam 321 73 99 93.2 7-26 
Midazolam 362 34 at pH 3, 
475 at pH 
7.4 
40-60 96 1-4 
*Note: Half-lives of benzodiazepines are shorter in patients with concomitant enzyme inducing drug therapy 
1.1.3.2.2. Absorptive Surface Area and Dose Volume Considerations 
 
Each route has certain physiological characteristics that effect selection of drug and 
formulation.  For example, all the routes have limited absorptive surface areas across 
which the drug must permeate to reach systemic circulation and a limited volume of fluid 
that can be instilled / injected into the tissue or cavity.  According to Fick’s Law of 
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diffusion (Equation (1)), the greater the absorptive surface area, the faster the drug 
absorption.   
………………………………………Equation (1) 
 Rectal and nasal routes have larger absorptive surface areas when compared to buccal, 
intramuscular and subcutaneous routes.  The volume of fluid that could be instilled or 
injected is as follows: Rectal cavity (~ 10mL) > IM (2-5 mL) > Subcutaneous and buccal 
(2 mL) > Nasal (~200 µL per nostril).  Routes which necessitate small volumes of fluid 
require potent drugs which are effective in small doses and/or can be formulated in very 
high drug concentrations.   
 
Shortly after the introduction of Diastat® (diazepam rectal gel), commercial development 
of innovative formulations began involving several BZDs and one or more routes of 
administration, including buccal, intramuscular, nasal, and subcutaneous. Table 3 provides 
an overview of benzodiazepine rescue therapies which are either approved, used off-label, 
and/or under development.  Currently, rectal diazepam (Diastat®) and buccal (BUC) 
midazolam (Epistatus® and Buccolam™, Europe only) are approved.  Investigational 
products include intranasal (IN), intramuscular (IM) and subcutaneous (SQ) formulations.   
 
Table 3. Benzodiazepine Seizure Rescue Therapies  
Route Drug Sponsor Development Status* 
Rectal Diazepam Valeant FDA-approved product for out of 
hospital treatment of acute repetitive 
seizures (Diastat®) 
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IN Diazepam Neurelis 
Neuronex/Acorda 
Phase I 
Phase II 
IN    Midazolam Upsher Smith Phase III 
IM  Diazepam King/Pfizer Phase III successfully completed.  
IM Midazolam Meridian/Pfizer Phase III completed 
SQ Diazepam Xeris Pharmaceuticals Pre-clinical phase 
Buccal Midazolam Specialty Products 
ViroPharma 
Marketed in selected European 
countries (Buccolam™ and Epistatus®) 
*Source of information: clinicaltrials.gov, press releases, grant awards, marketing information 
1.1.3.2. Route of Administration Considerations 
 
As discussed previously, both diazepam and midazolam have physico-chemical and PK 
properties which favor non-IV routes.  However, it is important to consider the 
significant differences in the rates of absorption when given by different extravascular 
routes.  A review of diazepam and midazolam pharmacokinetics literature following 
rectal, IN, IM, SQ and buccal administration is given below to identify and compare key 
differences between both drugs across each route of administration.   
1.1.4 Literature Review of Benzodiazepines Pharmacokinetics Following Rectal 
Administration 
 
1.1.4.1 General Considerations for Rectal Administration  
 
The rectal route is commonly used, particularly in young children, for the out-of-hospital 
treatment of seizure emergencies. Rectal administration is easily done by minimal 
training, partially avoids first pass metabolism and drug decomposition by stomach acids.  
 13 
 
The most common obstacle to rectal administration is social resistance or embarrassment. 
Other negative aspects to consider in rectal drug administration include the risk of drug 
expulsion, variable absorption, degradation of drug molecules by microorganisms, and 
adsorption to fecal material. 
1.1.4.2 Rectal Diazepam Pharmacokinetics in Healthy Volunteers 
 
Various diazepam formulations have been administered rectally including solutions, 
suppositories, and a gel. Table 4 summarizes results of several pharmacokinetic studies of 
rectal diazepam in healthy volunteers using the commercially available rectal formulation 
(Diastat®).  Results from pharmacokinetic studies conducted using diazepam solution 
and suppositories are not presented. 
 
Table 4. Pharmacokinetics of Rectal Diazepam in Healthy Volunteers 
Dose 
(mg) 
Sample 
size (N) 
Formulation Cmax 
(ng/mL) 
 
Tmax 
(hours) 
 
Comparator/ 
Other 
comments 
Ref. 
10 12 Diastat gel 160±109a 0.75  
(0.3-6.0)b 
IN 
microemulsions 
[30] 
10 20 Diastat gel 220 (39)c 0.5 
(0.17-1)b 
IM autoinjector [31] 
10 
10 
24 
24 
Diastat gel (IR)d 
Diastat gel (RR)e 
233 (42)c 
209 (44) 
1.4 (168)c 
0.6 (76) 
IM autoinjector  [32] 
15 
 
20 
 
Diastat gel 
 
447±91a 
 
1.18±0.6a 
 
IV infusion 
F = 90±10 % 
[33] 
a Mean ± SD  
b Median (range) 
c Mean (% CV) 
d IR – ‘Ideal’ rectal (diazepam given after a cleansing enema the evening prior to dosing, 
overnight fast, and another enema in the morning prior to drug administration) 
e RR – ‘Real’ rectal (diazepam given after a standard evening meal and bedtime snack on 
the day before dosing, and at 2 hours after a standard breakfast on the day of dosing) 
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An analysis of PK data in healthy volunteers from Table 4 confirms that there is high 
variability in both Cmax and Tmax when rectal diazepam gel is used.  Dose-adjusted 
mean Cmax ranged from 16–30 ng/mL/mg (% Co-efficient of variability (CV) range for 
Cmax across studies: 20-60%). Similarly, the rate of absorption was variable with Tmax 
ranging from 18 minutes to 6 hours (Mean: ~1 hour, %CV range across studies: 50-
168%).  The mean absolute bioavailability of rectal diazepam gel in one study was shown 
to be 90% [33].  Across several studies of rectal diazepam gel, intermediate to high 
variability in exposure was reported (%CV for AUC0-inf: 30-45%).   
1.1.4.3 Rectal Diazepam Pharmacokinetics in Patients 
 
PK studies of diazepam rectal gel in patients were not found in my literature review.  
However, results of a rectal solution administered to patients (Table 5), show similar or 
shorter Tmax on average compared to that seen with rectal gel in healthy volunteers. 
 
Table 5. Pharmacokinetics of Rectal Diazepam in Adult Patients 
Dose 
(mg) 
Sample 
size (N) 
Formulation Cmax 
(ng/mL) 
 
Tmax 
(hours) 
 
Comparator/ 
Other 
comments 
Ref. 
10 6 Rectal solution 309±68a 0.61±0.33a Oral tabs & IV 
F=81±13 
[34] 
10 6 Rectal solution Range  
(121-200) 
Range 
(10-20 min) 
IM and IV 
F=50±17% 
[35] 
a Mean ± SD  
 
1.1.4.4 Rectal Midazolam Pharmacokinetics 
 
In late 1980s and early 1990s, the results of pharmacokinetic studies involving rectal 
midazolam in infants, children, and adults following rectal midazolam administration 
were published [36-40].  Although average times to peak concentration were similar (~30 
 15 
 
minutes) compared to rectal diazepam, mean rectal bioavailability of midazolam was 
very low in both children (18%) and adults (52%).  This may be the reason why the 
commercial development of rectal midazolam has not been under taken.   
1.1.5 Literature Review of Benzodiazepines Pharmacokinetics Following Intranasal 
Administration 
1.1.5.1 General Considerations for Intranasal Administration 
 
Intranasal administration is simple, convenient, does not require patient cooperation, and 
offers potentially rapid and extensive absorption of highly potent, highly lipid soluble drugs, 
resulting in a fast onset of effect. Challenges include overcoming the necessity for very small 
dose volumes (< 200μL per nostril) and slow absorption due to limited absorptive area of the 
nasal cavity (200 cm2) that limit the potential for less potent, less lipid soluble compounds.  
Additional caveats include the need for understanding the effects of seizures on nasal 
absorption of these drugs, minimizing irritation of nasal tissues by organic solvents used in 
the formulations, and limiting loss of drug due to anterior or posterior drainage from the nasal 
cavity.  Several of the benzodiazepines have the requisite physico-chemical and 
pharmacokinetic properties to use in IN formulations for seizure emergencies (see Table 1) 
Within a few years after the introduction of diazepam rectal gel, there was an accelerated 
interest in developing a more acceptable approach/route to treat seizure emergencies.   To 
that end, IN formulations of both diazepam and midazolam were investigated to 
demonstrate the feasibility of this route in an emergency setting and pilot studies were 
conducted in healthy subjects to investigate both pharmacokinetics and tolerability of 
innovative formulations administered intranasally.   
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1.1.5.2 Intranasal Diazepam Pharmacokinetics in Healthy Volunteers 
 
Intranasal diazepam pharmacokinetics in healthy volunteers have been investigated and 
reported in several studies using various formulations of diazepam. Table 6 summarizes 
results of intranasal diazepam studies in healthy volunteers.  The intranasal formulations 
used by Agarwal et al [41] and Ivaturi et al [30] (shaded below in Table 6), or a close 
analogue, are under development in the US.    
 
Table 6. Pharmacokinetics of Intranasal Diazepam in Healthy Volunteers 
Dose 
(mg) 
Sample 
size (N) 
Formulation Cmax 
(ng/mL) 
Mean±SD 
Tmax 
(min) 
Median(range) 
F (%)a Ref
. 
10 
10 
24 
24 
Solution 
Suspension 
272±100 
221±78 
90 (48–240) 
60 (36-120) 
97 
67 
[41] 
10 
10 
13.4 
12 
12 
12 
Nas-A and B 
Microemulsions 
181±84 
151±108 
180±82 
45 (15 – 90) 
45 (15-180) 
45 (15-240) 
88* 
70* 
89* 
[30] 
10 
5 
8 
8 
60-40% V/V 
Glycofurol+H2O 
 
247±60 
134±60 
 
30 (10-120) 
20 (15-180) 
74±53 
75±41 
[42] 
5 3 60-40% V/V 
Glycofurol+H2O 
179±9 
 
28.8 ± 20.96b - [43] 
7  8 PEG 300 179(126-232)a 
 
42 (25-59) 42  
(22-62) 
[44]  
4 8 PEG 300 99 (83-115)a 
 
18 (11-25) 45  
(32-58) 
[44] 
2 9 PEG 200 + 5% 
Glycofurol 
39±17 
 
18±11b 50±23 [45] 
*Relative bioavailability compared to Diastat rectal gel 
a Mean (95% CI)  
b Mean±SD  
An analysis of diazepam pharmacokinetics reveals that absorption following intranasal 
administration appears to be somewhat faster (Median Tmax: < 1 hour) than rectal route 
based on Tmax (see Table 4 and 6).  However, average relative bioavailability of the IN 
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formulation studied by Ivaturi et al [30] was 70-90% relative to rectal formulation. It also 
has to be noted that there is intermediate to high variability in both Tmax and total drug 
exposure of diazepam given by the intranasal route (% CV range across studies: 30-50%).   
1.1.5.3 Intranasal Diazepam Pharmacokinetics in Patients 
 
A multi-center, open-label, PK study was conducted in 30 adult patients using 0.2mg/kg 
dose of diazepam nasal spray.  This study demonstrated that pharmacokinetics were not 
affected by seizure type or status at the time of dosing [46].  Dose-normalized average 
Cmax and AUC for patients dosed during a tonic-clonic ictal state relative to all other 
patients were similar (Mean Cmax: 194 vs. 215 ng/mL, and mean AUC0-12: 1258 vs. 
1212 h.mg/mL, respectively). However, Tmax was not reported.   
1.1.5.4 Intranasal Midazolam Pharmacokinetics 
 
Table 7 summarizes results of several reports describing pharmacokinetics of IN 
midazolam in healthy volunteers.   The IN formulation used by Wermeling et al [47] or a 
close analogue is being developed in US and has orphan designation.  Although not 
tested head-to-head, the time to reach Cmax for midazolam appears shorter than for 
diazepam (see Table 6 and 7).  Its bioavailability overlaps with diazepam, but trends 
toward a lower, intermediate range of 60-85%.  Thus, IN midazolam may have an 
advantage over diazepam due to its faster absorption.  Its shorter elimination half-life 
may be beneficial in that patients may more quickly return to normal function due to 
rapid offset of effect.  Alternatively, the faster rate of elimination may expose patients to 
a higher rate of seizure recurrence.  Ongoing clinical trials may provide insights into this 
issue. 
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Table 7. Pharmacokinetics of Intranasal Midazolam in Healthy Volunteers 
Dose 
 (mg) 
Sample 
Size 
(N) 
Formulation Cmax 
(ng/mL) 
Mean±SD 
Tmax 
(Minutes) 
Mean±SD 
F (%) 
Mean±SD 
Ref. 
2.5 
5.0 
7.5 
25 
25 
25 
USL261 
USL261 
USL261 
58.8 
73.5 
92.7 
Range for all 
doses: 11.5-
16 
73 SD? [48] 
5 
 
17 PEG 400 + Prop. 
Glycol 
83.9±29 
 
10 (5-20)a 60±23 [47] 
3 
6 
12 
12 
Beta CD + 
Chitosan 
52 (78)* 
97(49) 
8.4 (5-31)a 
7.6 (5-22) 
81(41 – 102)a 
76(52 – 102) 
[49] 
5 7 Propylene glycol 78±40 43±19 82±38 [50] 
3 
 
3 
 
8 
 
8 
Beta CD (12%) + 
Chitosan (0.5%) 
Beta CD (12%) 
80.6±15 
 
68.9±20 
7.2±1 
 
13±4 
76±12 
 
85±8 
[51] 
5 
 
6 Prop. Glycol 
+Water 
pH - 4 
71±25 
 
14±5 83±19 [52] 
5 
 
3 Aqueous  solution 
pH = 3 
62.8±14.51 21.6±7.63 - [43] 
12-20 
 
8 Aqueous solution 147 (91-
225)b 
 
25 (10-48)b 50±13 [53] 
CD: Cyclodextrin 
* Geometric mean (CV) 
a   Median (range) 
b   Mean (range) 
 
1.1.5.5 Intranasal Administration Summary 
 
Intranasal administration is a potential alternative for treatment of seizure emergencies in 
patients who object to rectal administration.  Pharmacokinetics in healthy volunteers 
show that absorption may be somewhat faster than rectal diazepam, but bioavailability is 
widely variable.  Two diazepam formulations and one midazolam formulation are being 
commercially developed in the US.   All three formulations can be administered in small 
dose volumes, with no evidence of second peaks in plasma concentration-time profiles 
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presumably due to delayed absorption from swallowing a portion of a dose.  Absorption 
from midazolam formulations appear to be relatively rapid compared to diazepam 
formulations but display lower bioavailability.  Decreased bioavailability issues can be 
overcome by administering a large enough dose, but high variability might become a 
problem. Variability in bioavailability was wide with both diazepam and midazolam 
formulations.  Nasal irritation following drug administration was noted in most studies 
with one exception (Agarwal et al [41]).  
1.1.6 Literature Review of Benzodiazepines Pharmacokinetics Following 
Intramuscular Administration 
1.1.6.1 General Considerations for Intramuscular Administration 
 
Intramuscular injections can be self-administered or can be given by a caregiver using auto-
injector devices as they do not require IV access.  Although simple and easy to self-
administer, some limitations of this route are pain at the injection site, need to remove 
clothing before administration, need for long needles (0.8-1.5 inch), and muscle mass 
related issues in elderly.  Interest in IM auto-injectors of benzodiazepines to treat seizure 
emergencies was sparked by the commercial success of Diastat.  An IM auto-injector of 
diazepam has been available for several years and is included in the Chempak (diazepam 
5mg/mL, auto-injector).   
1.1.6.2 Intramuscular Diazepam Pharmacokinetics   
 
Table 8 summarizes results of pharmacokinetics of diazepam given intramuscularly by an 
auto-injector.  The rate of absorption is slow to intermediate with average Tmax around 1 
to 1.5 hour across studies.  Although these trials did not include an IV arm in any of these 
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studies, one could assume that the bioavailability would be 100% by intramuscular route.  
Inter-individual variability in Cmax and AUC was wide (%CV: 20-30% for Cmax and 
30-60% for AUC).  This product was recently granted orphan designation in May 2013. 
Abou-Khalil et al. reported the results of a randomized, placebo-controlled study of IM 
diazepam auto-injector for treatment of ARS in which the drug was significantly better at 
preventing seizure recurrence when compared to placebo [54].   
Table 8. Pharmacokinetics of Intramuscular Diazepam in Healthy Volunteers 
Dose 
 (mg) 
Sample 
Size (N) 
Formulation/ 
Device 
Cmax 
(ng/mL) 
Mean(CV) 
Tmax 
(Minutes) 
Mean (CV) 
Comparator Ref. 
10 24 Meredian 
Medical Tech. 
Auto-injector 
(AI) 
303 (23) 52 (62) Rectal 
Diastat 
[32] 
5 
10 
15 
23 
23 
22 
King 
Pharmaceuticals 
/Meredian AI 
124 (31) 
226 (25) 
360 (28) 
60 (15 -75)a 
60 (15-90) 
60 (15-120) 
Rectal 
Diastat 
[31] 
10 
20 
24 
24 
Meredian AI 272 (33) 
511(22) 
94 (34) 
90 (35) 
None [55] 
a Median(range) 
1.1.6.3 Intramuscular Midazolam Pharmacokinetics 
 
Table 9 provides the pharmacokinetic results of intramuscular midazolam studies in 
healthy volunteers.  Intramuscular administration of midazolam using an auto-injector 
results in rapid absorption compared to IM diazepam (Median Tmax for IM midazolam is 
about 30 minutes and that for IM diazepam is about 1 hour).  Variability in Cmax and 
AUC was relatively low compared to diazepam (%CV: 13-35% for Cmax and 10-44% 
for AUC).   
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Midazolam has been shown to be most potent and rapidly acting in terminating soman-
induced seizures as compared to IM diazepam and IM lorazepam [56].  A non-inferiority trial 
funded by the Department of Defense and the National Institute for Neurological Disorders 
and Stroke compared the efficacy and safety of intramuscular midazolam (5-10 mg) versus 
intravenous lorazepam (2-4 mg) for children and adults in status epilepticus treated by 
paramedics.  Results of this study showed that intramuscular midazolam was superior to 
intravenous lorazepam in terminating seizures [57].  Both treatment groups were similar with 
respect to need for endotracheal intubation and recurrence of seizures.  As the IM route does 
not require establishing an IV line, the median time to initiate treatment was shorter (1.2 
minutes) in the midazolam group than in the IV lorazepam group (4.8 minutes), with a 
corresponding median time from initiating treatment to cessation of convulsions of 3.3 
minutes and 1.6 minutes, respectively. 
Table 9. Pharmacokinetics of Intramuscular Midazolam in Healthy Volunteers  
Dose 
 (mg) 
Sample 
Size 
(N) 
Formulation
/Device 
Cmax 
(ng/mL) 
Mean(CV) 
Tmax 
(Hours) 
Median 
(range) 
Comparator Ref. 
5 
10 
15 
20 
25 
30 
4 
3 
8 
5 
9 
10 
Meredian 
Medical 
Tech. Auto-
injector 
(AI) 
61.3(13.5) 
111.2(27.1) 
196.6(26) 
207.2 
(34.6) 
266.9(15.9) 
417.7 
(25.8) 
0.6 (0.5, 0.75) 
0.5 (0.25, 0.5) 
0.4 (0.25, 
0.85) 
0.5 (0.33, 
1.00) 
0.5 (0.33, 
0.75) 
0.5 (0.25, 1.5) 
None [58] 
5 4 Conventional 
IM injection 
100.5 (21) 0.3 (0.15, 0.4) Conventional 
IM diazepam 
injection 
[59] 
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1.1.6.4 Intramuscular administration Summary 
 
Intramuscular administration of benzodiazepines offers a potential alternative to 
treatment of out-of-hospital seizure emergencies.  Midazolam, given by the intramuscular 
route, is absorbed faster than diazepam and is the preferred benzodiazepine when given 
by this route.  A diazepam auto-injector is being developed for marketing in US and has 
orphan designation for ARS. Midazolam auto-injector has orphan designation for soman-
induced seizures and may be developed for marketing.   
1.1.7 Subcutaneous Administration 
 
There are no published pharmacokinetic studies of diazepam given subcutaneously to 
humans.  Two pharmacokinetic studies of midazolam given subcutaneously were found 
in literature [60, 61].  Healthy subjects received single doses of 0.05-0.1mg/kg of 
subcutaneous and IV midazolam.  In both studies, average Tmax was in the range of 25-
30 minutes.  Pecking et al. reported average Tmax (SD) and absolute bioavailability (SD) 
in their study to be 0.5 (0.18) hours and 96 (14)% respectively [60].    
1.1.8 Buccal Administration  
 
Midazolam has been studied by this route by several investigational groups. Two 
products (EpistatusTM and Buccolam®) are commercially available in the United 
Kingdom.  Muchohi et al [62] investigated the pharmacokinetics of buccal midazolam in 
8 children with severe malaria and convulsions.  Median (range) Cmax of 186 (64-394) 
ng/mL were attained within a median (range) Tmax of 10 (5-40) minutes following 
administration.  A study of buccal and intravenous midazolam pharmacokinetics in 8 
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healthy volunteers indicated that the buccal absorption is comparable to rectal diazepam 
with good bioavailability [63].  Scott et al. studied the buccal midazolam administration 
in 10 healthy volunteers who were administered 2mL of the intravenous preparation of 
midazolam (5mg/mL), flavored with peppermint. The subjects were asked to hold the 
solution in the mouth for 5 minutes and then spit it out.  Changes in EEG were observed 
within 5 to 10 minutes after drug administration indicating rapid absorption and onset of 
effect [64]. 
1.1.9 Development of Intranasal Diazepam for Management of Acute Repetitive 
Seizures 
 
Intranasal benzodiazepines appear to be particularly promising and several research 
groups have carried out studies to investigate the pharmacokinetics, bioavailability and 
tolerability [65-77].  Diazepam has been proven safe and effective and has been used for 
about 15 years for treatment of ARS.  It is likely that clinicians would be more comfortable 
prescribing IN diazepam because of their clinical experience with diazepam in ARS patients.  
For IN diazepam, market approval of a commercial product is possible without conducting a 
safety and efficacy trial.   A sponsor of IN diazepam could rely on efficacy performance of 
rectal diazepam and conduct only pharmacokinetics and safety studies for intranasal 
diazepam, but not necessarily a well-controlled, efficacy and safety trial. In contrast, 
clinicians lack such experience with midazolam in ARS patients and a midazolam product 
will need a well-controlled trial to show efficacy.  From a drug development perspective, it 
would be more cost effective to conduct safety and PK studies for IN diazepam than to 
conduct a well-controlled efficacy trial for nasal midazolam. 
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1.2 Spasticity 
 
Spasticity is defined as velocity-dependent resistance to movement associated with 
increased deep tendon reflexes and clonus.  Spasticity is a well-known muscle tone 
disorder, characterized by tight or stiff muscles.  In addition, reflexes may persist for too 
long and may be too strong (hyperactive reflexes).  Spasticity occurs in disorders of the 
central nervous system (CNS) affecting the upper motor neuron (Figure 3) [78], most 
commonly arising after stroke, multiple sclerosis, spinal cord injury (SCI), some 
traumatic brain injuries, cerebral palsy and other CNS lesions.    Causes of spasticity 
may include tumor, central nervous system infarct, neurodegenerative disorders, 
metabolic disorders, or hydrocephalus.   
 
Figure 3: Upper Motor Neuron Injury Level Causing Spasticity  
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In general, spasticity develops when an imbalance occurs in the excitatory and inhibitory 
input to α motor neurons caused by damage to the spinal cord and/or brain [79].  The 
damage causes a change in the balance of signals between the nervous system and the 
muscles, leading to increased tonicity in the muscles.  Spasticity affects approximately 
70% of those with cerebral palsy (CP) and is the most common tonal abnormality 
associated with CP [80]. Dystonia is another common type of increased muscle tone 
associated with CP. Dystonia is defined as an involuntary alteration in the pattern of 
muscle activation during voluntary movement.  Dystonia is characterized by varying tone 
often increased with intent or emotion and associated with assuming abnormal postures 
[81].  Hypertonicity in muscles interferes with functional abilities and contributes to the 
development of bony deformities and contractures.  The pain associated with spasticity 
can be as mild as a feeling of tight muscles, or it can be severe enough to produce painful 
spasms of the extremities, usually the legs.  Spasticity also can cause low back pain and 
result in feelings of pain or tightness in and around joints.  
 
The presence of spasticity alone is not considered sufficient to warrant its treatment [82].  
It is essential to set goals that are to be achieved through spasticity reduction.  Treating 
spasticity will improve functional abilities and limit contracture formation [83].  
Treatment for spasticity may include medications like baclofen, clonidine, tizanidine, 
dantrolene, gabapentin, diazepam, or clonazepam. Occupational and physical therapy 
programs, involving muscle stretching and range of motion exercises, and sometimes the 
use of braces, may help prevent tendon shortening.  Rehabilitation also may help to 
reduce or stabilize the severity of symptoms and to improve functional performance.  
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Local injections of phenol or botulinum toxin may be used to relax specific muscles. 
Surgery may be recommended for tendon release, to cut the nerve-muscle pathway, or to 
implant a baclofen pump (intrathecal baclofen therapy). No single medication has been 
universally effective in the treatment of spasticity [84], which is not surprising given that  
spasticity is a result of multiple factors caused by several different mechanisms.  Table 10 
and Figure 4 provide the sites and mechanisms of action of anti-spasticity medications. 
Table 10. Sites and Mechanisms of Action of Anti-spastic Drugs [78] 
Drug Site of Action Mechanism of Action 
Diazepam and Clonazepam Spinal cord – presynaptic 
inhibition 
Increase GABA affinity for 
GABAA receptors 
Baclofen Spinal cord – presynaptic 
inhibition 
Binds to GABAB receptors 
Clonidine and Tizanidine Spinal cord Hyperpolarize neurons, 
decrease excitatory amino 
acids, possible role of 
substance P 
Dantrolene Sodium Skeletal muscle Inhibits release of calcium at 
sarcoplasmic reticulum 
Gabapentin Spinal cord GABA  
 
 
Figure 4: Sites of Action of Anti-Spasticity Drugs [85] 
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1.2.1 Baclofen  
 
Baclofen is used in the treatment of spasticity. Its mechanism of action is to act at the 
level of spinal cord as an agonist at GABAB receptors.  It suppresses the release of 
excitatory neurotransmitters and results in presynaptic inhibition, inhibition of mono- and 
poly-synaptic reflexes [86], reduces muscle-spindle activity and reduces gamma motor 
activity.  It is available both as tablets and as an injectable solution, of which the latter is 
used in intrathecal pumps. The GABAB activity of racemic baclofen is known to be due 
to R-(-)-enantiomer (Figure 5) [87]. Table 11 shows the physicochemical properties of 
baclofen.   
 
Figure 5: Chemical Structure of R-(-) Baclofen. Chemical name: 4-amino-3-(4-
chlorophenyl) butanoic acid 
 
Table 11.  Physico-chemical Properties of Baclofen [88]  
Molecular 
Weight 
pKa 
 
Water 
Solubility 
(mg/mL)  
Octanol/Water 
Ratio [89] 
Protein Binding 
(%) [90] 
213.6 4 4.3 0.11 30 
 
1.2.1.1. Oral Baclofen  
 
Baclofen is rapidly absorbed when given orally and eliminated with a plasma  half-life of 
3-7 hours [91].  85% of baclofen is excreted unchanged in urine and feces, while 15% is 
metabolized [92].  Adults are typically started on 5 mg three times a day orally and then 
titrated up 5 mg every 3 days until optimal effect is achieved.  Some patients, to 
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experience adequate symptomatic relief, require dosages of baclofen that significantly 
exceed the conventional 80 mg daily maximum [93].  However, as the doses are 
increased, side effects such as somnolence, dizziness, and muscle weakness are observed 
[94].  Baclofen given orally often fails to produce sufficient relief.  This could be 
possibly due to low bioavailability of drug at the site of action (spinal cord).  
Bioavailability at spinal cord can be markedly improved by local administration of 
baclofen at the site of action i.e., intrathecal drug delivery.  Intrathecal administration of 
baclofen in the treatment of severe spasticity was proposed in 1984 by Richard Penn [95]. 
1.2.1.2. Intrathecal Baclofen 
 
The introduction of intrathecal baclofen (ITB) served to address some of the 
shortcomings of oral baclofen. Patients on intrathecal baclofen need lower doses and 
typically start with 50-100 mcg/day and are titrated up 5-15% of the dose once every 24 
hours until optimal effect is achieved.  Intrathecal therapy has the potential to lower side 
effects by reducing drug exposure at supraspinal sites.  Other advantages include minimal 
protein binding and enzymatic degradation in cerebrospinal fluid (CSF) compared to 
plasma, leading to longer half-life in CSF [96, 97].  ITB is pumped slowly into the 
cerebrospinal fluid (CSF) at the subarachnoid space by an implanted catheter, allowing 
for reduced, but still efficacious doses to be delivered at the site of action with much 
smaller systemic exposure. ITB is an option for patients with spasticity or dystonia 
unresolved by other pharmacological and non-pharmacological treatments. Furthermore, 
patients who do not respond sufficiently to oral baclofen may respond to ITB [98].  To 
understand factors affecting spinal drug delivery, presented below is a discussion of 
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anatomy of spinal cord, physiology of CSF, and movement of drug following epidural 
and intrathecal drug delivery. 
1.2.2 Anatomy of Spinal Cord 
 
The spinal cord is about 16-18 inches long and is basically a uniform structure throughout 
its length. The spinal cord is contained in the vertebral arch (back bone) which protects it 
from injury. It has an inner mass of gray matter and an outer covering of white matter. It 
carries messages that coordinate movement and sensation. The cord is an ovoid shaped 
column of nerve tissue that extends from the medulla at the underside of the brain down 
in the spinal column to the second lumbar vertebrae. The spinal cord is protected by the 
bones of the spinal arch and enclosed in the protective tissue of the three meninges (dura 
mater, arachnoid mater and pia mater) and CSF. The center of the cord is gray matter and 
shaped like an H (Figure 6). The white matter is arranged in tracts around the gray matter 
and consists of axons that transmit impulses to and from the brain or between levels of 
gray matter in the spinal cord. 
 
The spinal cord has two basic functions. It can act as a nerve center and can work without 
the brain. The spinal cord carries sensory impulses to the brain and motor impulses from 
the brain. The spinal cord also controls reflexive activity such as stretch reflexes, bowel 
and bladder control, and withdrawal from a painful stimulus. The brain can sometimes 
modulate these reflexive activities. Thirty-one pairs of nerves exit from the spinal cord 
and innervate our body and limbs. The spinal cord also acts as a nerve center between the 
brain and the rest of our body. 
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Figure 6: Anterior View and Transverse Section Through Spinal Cord [99] 
1.2.3 Physiology of Cerebrospinal Fluid 
 
1.2.3.1 CSF Formation 
 
The rate of CSF formation is about 0.35-0.40 ml/min or 500-600 ml/day in humans.  
Approximately 0.25% of total adult CSF volume is replaced by freshly formed CSF each 
minute.  The turnover time for total CSF volume is about 5-7 hours, yielding a turnover 
rate of about four times per day.  Roughly 40-70% of CSF enters the macroscopic spaces 
via the choroid plexus, whereas 30-60% of CSF enters the macroscopic spaces from 
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extrachoroidal sites.  Total CSF volume in man is 100-160 ml with ventricular volume 
being 16-27 ml.   
 
Unlike the capillary endothelium (CE) of the blood-brain-barrier, the CE of the choroid 
plexus is fenestrated and does not possess tight junctions between cells (Figure 7).  Blood 
entering choroid plexus capillaries is filtered across this endothelium and forms a protein-
rich fluid within the choroid plexus stroma that is similar in composition to interstitial 
fluid in other tissues of the body.  The choroid plexus stroma is separated from 
macroscopic CSF spaces by epithelial cells.  These contain apical tight junctions that 
restrict passive solute exchange and constitute a “blood-CSF barrier” at the choroid 
plexus.  Substances in the choroid plexus stromal fluid are transported across the 
relatively impermeable epithelial cells of choroid plexus by the combined processes of 
ultrafiltration and secretion.  60% of the extrachoroidal formation of CSF results from 
oxidation of glucose by the brain, and 40% results from ultrafiltration from cerebral 
capillaries.  A very negligible amount of CSF forms in the spinal cord. 
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Figure 7: Processes Involved in CSF Formation at the Choroid Plexus [100] 
 
1.2.3.2 CSF Circulation 
 
Radioisotope studies indicate that labeled CSF flows from the ventricles to the basal 
cisterns within a few minutes, low cervical-high thoracic region at 10-20 minutes, 
thoracolumbar area at 30-40 minutes, lumbosacral cul de sac at 60-90 minutes, and basal 
cisterns at 2-2.5 hours [101] (round trip from brain to spinal cord to brain).  About 20-
33% of the labeled CSF reaches the intracranial cavity within 12h.  CSF circulation 
concludes with reabsorption across arachnoid villi into the superior sagittal sinus and 
spinal dural sinusoids located on dorsal nerve roots.  Circulation of CSF is not 
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substantially altered by posture or ambulation, although physical activity perturbs CSF 
concentration gradients by promoting CSF mixing.  
1.2.4 Drug Kinetics Following Spinal Administration 
 
Similar to any other route of administration, drugs injected into the epidural or intrathecal 
space follow Fick’s law of diffusion and can be transported actively.  The drug molecules 
will move down a concentration gradient by simple Brownian motion until they partition 
into the micro-environments (eg: epidural fat, collagen, CSF, white matter, myelin etc.,) 
in which they are thermodynamically most stable.  The physicochemical properties of the 
drug play a crucial role in determining which micro-environment it will partition to, 
which in turn determines the bioavailability of a given drug at its intended target site.  For 
example, a drug which is lipophilic will preferentially distribute and get sequestered into 
epidural fat and will not be highly available in the gray and white matter of spinal cord. 
Delivery of drugs into intrathecal or epidural space can achieve target site concentrations 
that are not readily attainable following conventional routes such as oral or intravenous 
delivery.  Additional advantage from such delivery is to restrict drugs to their spinal site 
of action thereby avoiding drug related systemic side-effects or toxicities.  It is important 
to understand the factors affecting drug distribution from the epidural and intrathecal 
space to the spinal cord while limiting redistribution to extra-spinal sites. 
1.2.4.1 Systemic Distribution 
 
Physico-chemical properties of the drug will govern the rate at which drug enters 
systemic circulation.  It is interesting to note that rate of clearance from epidural space of 
etidocaine (a relatively hydrophobic, highly plasma protein bound (94%) drug) from the 
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epidural space is significantly slower than that of lidocaine (a relatively hydrophilic, less 
protein bound (64%) drug).  So, this suggests that increasing lipid solubility allows drugs 
to be effectively sequestered into epidural fat.  In combination, increased protein binding 
with high drug lipophilicity leads to longer drug residence time in epidural space. 
1.2.4.2 Drug Distribution through Spinal Meninges to Spinal Cord 
 
Drug distribution through the spinal meninges has been demonstrated to occur by simple 
diffusion in vitro [102-105].  Though possible, there is no evidence for active transport or 
facilitated diffusion of drug molecules through spinal meninges [106].  Conventional 
principles of drug diffusion suggest that increasing lipid solubility would result in greater 
drug permeability through the spinal meninges.  Bernards and Hill [104] studied eight 
drug molecules and found no relationship between the drugs' permeability coefficients 
determined using the spinal meninges of monkeys and any measure of drug mass, 
molecular shape, or molecular size. There was, however, a biphasic relationship between 
the octanol: buffer distribution coefficient and the drugs' measured permeability 
coefficients. Drugs that were either very hydrophilic or very hydrophobic had 
permeability coefficients that were significantly less than drugs of intermediate 
hydrophobicity (Figure 8).  One explanation for such “biphasic” relationship would be, as 
hydrophobicity increases presumably hydrophobic drugs may effectively get sequestered 
in the lipid bilayer of the arachnoid membrane.  The same hydrophobic character which 
renders a drug to readily partition into the lipid bilayer of the cell membrane would lead 
to difficulty in partitioning out of the cell membrane to re-enter the aqueous intra- or 
inter-cellular space.  Hydrophilic drugs would be expected to have quite the opposite 
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problem.  They would have difficulty entering the lipid bilayer at the first place.  Thus, 
drugs with intermediate hydrophobicity (log P of 2) will move through the arachnoid 
mater most rapidly.  Although this explanation is not proved, it has been used 
successfully to increase the meningeal permeability of both hydrophilic and hydrophobic 
drugs.  One way to improve the permeability of hydrophobic drugs is to increase their 
aqueous solubility.  For example, combining sufentanil (lipophilic compound) with 
hydroxypropyl-b-cyclodextrin increases sufentanil’s permeability across meninges by 
more than 2 fold in vitro [107].  Similarly, in vitro studies demonstrate that the meningeal 
permeability of hydrophilic drugs can be increased by addition of acyl-carnitines to the 
drug solution [105, 108].  Baclofen has a log P value of -0.96 and it preferentially 
partitions into hydrophilic environment.  Using the model described above, baclofen 
given epidurally will not diffuse through arachnoid membrane.  Addition of acyl-
carnitines to baclofen might be helpful in increasing the permeability across spinal 
meninges. 
 
 
 
 
 
 
 
 
 
 
 36 
    
Figure 8: Plot of Octanol: buffer (pH = 7.4) Distribution Coefficient vs. the 
Experimentally Determined Permeability Coefficient; 
 (a = alfentanil; b=bupivacaine; c=lidocaine; d=haloperidol; e=fentanyl; f=sufentanil; 
g=morphine; h=tetracycline) 
1.2.5 Drug Kinetics Following Intrathecal Administration 
 
One would expect that the drug behavior in the CSF would be independent of whether it 
got there by diffusing across the spinal meninges from the epidural space or was injected 
directly into CSF.  However, this is not the case.  Direct injection into CSF via spinal 
needle or catheter produces different “initial conditions” compared to drugs which were 
initially delivered into epidural space.  Intrathecal injection results in mixing of injectate 
with CSF, which does not occur with epidurally administered drugs.  In addition, the 
patient position at the time of injection also affects the initial distribution of hyperbaric 
and hypobaric drugs.   
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One other factor which affects the initial distribution of intrathecal drugs is the baricity.  
Baricity is defined as the ratio of the density of the injectate compared to the density of 
CSF which averages 1.0003 g/mL at 37 degree centigrade.   Hyperbaric solutions 
(density >1 g/mL) will move down in the CSF column in response to gravity to rest in the 
most dependent portion of the spinal column.  In contrast, hypobaric solutions move up 
the CSF column and isobaric solutions (though difficult to make as we don’t know the 
density of CSF of an individual exactly) don’t move in response to gravity.  Hyperbaric 
and hypobaric solutions only move until the solution is sufficiently diluted by CSF so that 
it becomes isobaric.   
1.2.5.1 Drug Movement in Cerebrospinal Fluid 
 
CSF flow within spinal canal significantly affects the distribution of drugs.  CSF is 
produced within the brain and reaches the spinal cord by flowing caudal along the dorsal 
aspect of the spinal cord to the sacral cul de sac and then flows rostrally along the ventral 
surface of the cord to reach the basal cisterns.  The total “round-trip” time in humans is 2-
2.5 hours.  In conjunction to flow of CSF, there is also a pulsatile to and fro motion 
imparted to the CSF by the normal pulsatile motion of the brain that occurs with heart 
beat.   
1.2.5.2 Drug Clearance from Cerebrospinal Fluid 
 
Drug in CSF is rapidly removed by uptake into spinal cord and also by diffusion across 
the meninges and into the epidural space.  Drug clearance from the CSF can be studied 
by sampling CSF via a catheter at various time points following intrathecal injection.  
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However, this methodology has two shortcomings.  One is that the method of sampling 
itself disturbs the CSF distribution of the drug by creating CSF turbulence and may 
thereby alter the drug’s elimination kinetics.  The second and even greater shortcoming is 
that it does not yield any information about the site to which the drug is cleared, which is 
critical information since one is rarely targeting the CSF per se.   
 
Loss of drug to the epidural space is an underappreciated source of drug removal.  In vivo 
studies in pigs show that 60% of the intrathecal dose of morphine was lost to the epidural 
space and the remaining was cleared into the spinal cord [109].  In the same study it was 
found that the epidural fat appears to act as a site for sequestration of intrathecally 
administered fentanyl and sufentanil.  Loss of lipophilic drug to epidural space is greater 
than hydrophilic drugs and therefore, the bioavailability of lipid soluble drugs within the 
spinal cord receptors is much less than that of more hydrophilic drugs. 
1.2.5.3 Drug Movement in Spinal Cord 
 
Drugs administered in the epidural space or intrathecal space partition into the spinal cord 
by diffusion to reach the specific neuronal or receptor population that is being targeted.  
Spinal cord has two very different environments into which the drug molecules can 
diffuse (Figure 6). The outer portion of the spinal cord which is called white matter 
consists of myelinated axons running between the brain and spinal cord.  The white 
matter surrounds the inner portion of the cord which is called gray matter.   
Gray matter consists of unmyelinated neuronal cell bodies.  Presence of myelin in the 
white matter is perhaps the most important difference between the gray and white matter 
with respect to drug diffusion in these two environments.  Myelin is composed of 70% 
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lipid and 30% protein.  Therefore, white matter largely represents a relatively 
hydrophobic environment compared to the gray matter and hydrophobic drugs would 
preferentially accumulate in it.  In contrast, gray matter which consists of unmyelinated 
neuronal cell bodies will preferentially accumulate hydrophilic drugs.  This preferential 
partitioning of hydrophilic and hydrophobic drugs in gray and white matter, respectively 
has not yet been adequately studied.  So, it cannot be said with certainty if drugs will 
distribute within the spinal cord as predicted.  However, drug movement in the brain has 
been extensively studied and can provide important clues for drug movement in spinal 
cord.   
 
Herz and Teschemacher [110] injected radiolabeled morphine, hydromorphone and 
fentanyl into the lateral cerebral ventricle of rabbits and measured the depth of drug 
penetration at various times using autoradiography.  They found that the hydrophilic 
drugs morphine and hydromorphone penetrated much deeper into the brain than the 
relatively hydrophobic drug fentanyl.  It was also pointed out that fentanyl preferentially 
accumulated in the white matter and the other two drugs preferentially accumulated in the 
gray matter.   Consequently, one would expect the bioavailability of lipid soluble drugs in 
the gray matter to be limited and therefore lead to reduced intensity and duration of drug 
effect if the site of action is in gray matter.  For example, the relative analgesic potency 
of sufentanil compared to morphine in humans is approximately 20-40 times less 
following intrathecal administration compared to intravenous administration.   
1.2.6 Transport of Baclofen from Systemic Circulation to Site of Action  
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Baclofen is currently available as oral tablets and an injection solution which is used in 
intrathecal pumps.  When given orally it first gets absorbed into systemic circulation and 
then has to reach the site of action before it can elicit its therapeutic (eg: antispasticity) or 
side effects.  The site of action for its antispastic effect is spinal cord and for some of the 
side effects such as sedation, dizziness and ataxia is brain.  Therefore, one can conclude 
that baclofen can enter both into brain and spinal cord when given orally although the 
mechanism of transport to site of action is unknown.   
 
From the above discussion, one can propose the following three mechanisms for baclofen 
transport from blood to its site of action in spinal cord. 
1. Passive diffusion through spinal meninges into intrathecal space.  The octanol-water 
distribution coefficient of baclofen is 0.11 (Log P = -0.96) [89].  From Figure 8, one can 
infer that a molecule with a log P value of 2 will diffuse rapidly through spinal meninges.  
Given the low lipophilicity of baclofen, passive diffusion across spinal meninges would 
be limited as the lipophilic arachnoid mater will act as a barrier to drug diffusion. 
2. Although possible but not supported by any evidence, active transport of baclofen 
from blood across the spinal meninges and then into intrathecal space. 
3. Transport of baclofen from Blood to Choroid Plexus to CSF and then percolation 
down into spinal canal.  The transport of baclofen from blood to choroid plexus and 
eventually to CSF could be from passive diffusion and/or active transport at the tight 
junctions of epithelial cells of blood-CSF-barrier. 
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Baclofen concentrations determined by microdialysis after intravenous administration in 
rats were 27-fold higher in plasma than in interstitial fluid (ISF), whole brain tissue and 
CSF in [111].  This is regarded as surprising [89] because it was previously found to be a 
substrate of the neutral amino acid transporter [112], which should also be present in the 
BBB [113].  One hypothesis for limited distribution of baclofen to the CNS could be due 
to the affinity to an effective probenecid sensitive efflux system for organic anions [111].   
1.2.7 Baclofen Withdrawal 
 
Baclofen withdrawal occurs due to interruption in oral baclofen therapy as a result of illness 
such as gastroenteritis or ileus, non-compliance, or a scheduled surgery for which patients 
must temporarily stop taking oral medications.  It could be also a result of interruption of 
intrathecal baclofen under circumstances of catheter displacement from the intrathecal space, 
pump infection or some other reasons of mechanical failure of pump.  Baclofen withdrawal 
syndrome can be quite severe, resulting in a rebound increase in muscle tone and spasms, 
prolonged seizures, status epilepticus, hallucinations, dysesthesias, hyperthermia, and a 
neuromalignant syndrome-like picture potentially resulting in rhabdomyolysis and 
multisystem organ failure [114-120] .  Some of these symptoms are due to withdrawal of 
baclofen from cerebral receptor sites.  Therefore to treat baclofen withdrawal successfully, it 
is important to target both brain and spinal cord receptors.   
1.2.8 Current Treatment Strategies and Limitations 
 
The current recommended management of baclofen withdrawal is inadequate. In the case of 
interruption of ITB therapy, attempts to replace the medication with oral baclofen require 
large doses in an effort to control withdrawal symptoms [116, 121].  Moreover, in spite of 
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using large doses, symptoms are not controlled completely and adverse effects including 
sedation, nausea, vomiting and dizziness may occur.  Diazepam is used by most clinicians for 
its anti-spasticity effect and to decrease the likelihood of acute seizures; however, could 
result in sedation and respiratory depression [116, 122].    
1.2.9 Intravenous Baclofen for Management of Baclofen Withdrawal 
 
Use of an intravenous (IV) baclofen formulation could prevent or minimize the complications 
in individuals in whom oral or intrathecal drug delivery is interrupted.  Intravenous 
administration of baclofen would permit rapid attainment of drug concentrations as well as 
accurate and precise dose titration, thus allowing for more expeditious treatment of 
withdrawal symptoms and reduced risk of adverse effects. 
1.2.10 Development of Intravenous Baclofen  
 
Although oral and intrathecal baclofen have been used for decades, safety and PK of 
intravenous baclofen in humans is not well characterized.  While there are several reports of 
IV baclofen administration in both animals and humans [123-126], details of the formulation 
used in these studies and pharmacokinetic results were not reported.  In addition, very limited 
information was provided about the dose selection and adverse events in these studies.  An 
FDA-approved intravenous formulation of baclofen is not currently available.  A recent 
clinical study in patients used an extemporaneously compounded sterile formulation of 
baclofen (2.5mg/mL, pH 6.6) to reduce pain from muscle spasm and migraines (J Krusz, 
personal communication 2013).    
 
These circumstances suggest that a FDA-approved commercial IV baclofen product would 
enhance management of patients with spasticity.  The first step in the development of such a 
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product is demonstration of its safety in an animal model.  Therefore, a pilot study in dogs 
was conducted to assess the bioavailability, short-term safety, and tolerance of intravenous 
baclofen in comparison to oral administration.  IV baclofen at doses of 0.5 to 3 mg/kg was 
well tolerated in dogs [127].  The next phase in the development of an IV baclofen 
formulation is to conduct a series of investigations in humans.  To that end, a pilot study was 
conducted to assess pharmacokinetics using non-compartmental analysis, and the 
tolerability of baclofen given intravenously to healthy volunteers. 
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DISSERTATION RESEARCH OBJECTIVES 
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2.1 Development of Intranasal Diazepam for Management of Seizure Emergencies 
To meet the need for an alternate therapy for seizure emergencies, we have investigated 
several intranasal (IN) formulations of diazepam.  Studies conducted in our research 
group have demonstrated the feasibility of nasal administration of diazepam.  Diazepam 
was absorbed rapidly following nasal administration and the pharmacokinetic (PK) 
profile of IN formulations compared favorably to that of the rectal diazepam gel. 
However, the tolerability was only moderate.   
The results of earlier studies concluded that IN diazepam offers a viable alternative to 
rectal administration.  However further enhancement of formulations was needed to both 
improve tolerability and the extent and consistency of absorption.  To that end, two novel 
formulations of diazepam nasal spray were developed.  A pilot study was conducted to 
characterize the PK and tolerability of these two novel nasal formulations of diazepam.  
Further, in addition to data from current work, archived rectal and intravenous diazepam 
PK data from five previously conducted studies were combined to build a population PK 
model and perform simulations to optimize future bioequivalence trials.  The specific 
research objectives include: 
1. Assessment of the PK using non-compartmental analysis, and tolerability of two 
different formulations of intranasally- administered diazepam.  
2. Development of a PK model, using non-linear mixed effects modeling approach, 
to characterize diazepam absorption and disposition. 
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3. Perform a simulation study to test the hypothesis that an investigational IN 
product will produce exposure similar to that obtained following rectal 
administration. 
4. Perform deconvolution analysis to compare the absorption characteristics of 
diazepam after IN and rectal administration 
2.2 Development of Intravenous Baclofen for Management of Baclofen Withdrawal 
To enhance management of patients with spasticity, our research group has proposed 
development of IV baclofen.  A pilot study in dogs showed that 0.5- 3 mg/kg single doses 
of IV baclofen were well tolerated by dogs.  The next phase in the development of an IV 
baclofen formulation would be to conduct a series of investigations in humans.  To that 
end, a pilot study was conducted to assess PK and tolerability of baclofen given 
intravenously to healthy volunteers.  The specific research objectives are: 
1. Assessment of the PK, using non-compartmental analysis, of orally and 
intravenously administered baclofen, and  
2. Assessment of tolerability of intravenously administered baclofen.  
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2.3 My Role in Projects 
 
Grant applications 
Co-wrote and submitted two grant applications to Paralyzed Veterans of America 
Research Foundation for the following studies: 
• Two-way crossover study of oral and intravenous baclofen in healthy adults 
• Dose escalation study of intravenous baclofen in healthy adult volunteers 
Investigational new drug applications 
• Prepared and submitted an investigational new drug (IND) amendment for use of 
intranasal diazepam in healthy adult volunteers 
• Prepared and submitted an investigational new drug (IND) application for use of 
intravenous baclofen in healthy adult volunteers 
• Prepared and submitted an investigational new drug (IND) amendment for use of 
escalating doses of intravenous baclofen in healthy adult volunteers 
Phase 1 study of two intranasal formulations of diazepam in healthy adult volunteers 
• Assisted with designing the study and co-wrote the protocol 
• Prepared, submitted and got approval for an IRB application 
• Prepared and submitted an investigational new drug (IND) amendment for use of 
intranasal diazepam in healthy adult volunteers 
• Served as study coordinator, supervised and managed the study 
• Analyzed the pharmacokinetic data using non-compartmental analysis, non-linear 
mixed effects modeling, and deconvolution approach 
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• Developed an Orphan Drug Designation Application for Diazepam Nasal Spray 
Product 
Two-way crossover study of oral and intravenous baclofen in healthy adult volunteers 
• Designed the study and co-wrote the protocol 
• Prepared, submitted and got approval for an IRB application 
• Prepared and submitted an investigational new drug (IND) application for use of 
intravenous baclofen in healthy adult volunteers 
• Co-wrote and submitted a grant application to Paralyzed Veterans of America 
Research Foundation 
• Served as study coordinator, supervised and managed the study 
• Analyzed the blood plasma samples for baclofen concentrations using a validated  
liquid chromatography/mass spectrometry based assay.   
• Analyzed the pharmacokinetic and safety data 
Dose escalation study of intravenous baclofen in healthy adult volunteers 
• Designed study and co-wrote the protocol 
• Prepared, submitted and got approval  for an IRB application 
• Prepared and submitted an investigational new drug (IND) amendment for use of 
escalating doses of intravenous baclofen in healthy adult volunteers 
• Co-wrote and submitted a grant application to Paralyzed Veterans of America 
Research Foundation 
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DEVELOPMENT OF INTRANASAL DIAZEPAM FOR MANAGEMENT OF 
SEIZURE EMERGENCIES 
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 3.1 A Pilot Study Assessing the Bioavailability and Pharmacokinetics of Diazepam 
after Intranasal and Intravenous Administration in Healthy Volunteers1 
 
3.1.1 Introduction 
Seizure emergencies are associated with high morbidity and mortality which can be 
reduced by prompt and appropriate pharmacological therapy.  During a seizure, there is 
an increased release of excitatory neurotransmitters, usually glutamate and/or aspartate. 
Normally, an increase of the inhibitory neurotransmitter, gamma aminobutyric acid 
(GABA) will result in cessation of the seizure [128].  However, if GABA is not released 
promptly, excess excitation may lead to loss of neural control and convulsive seizures.  In 
1993, Epilepsy Foundation of America’s Working Group on Status Epilepticus  
recommended that antiepileptic drug administration should be initiated whenever a 
seizure has lasted 10 minutes [129].  A recent review article suggested that most epileptic 
seizures last 1-4 minutes and seizures lasting greater than 5 minutes should be treated as 
status epilepticus [130].  Evidence suggests that the longer a seizure continues, the less 
likely it is to spontaneously stop [131] and can also progress to status epilepticus, which 
is associated with increased morbidity and mortality, suggesting a need for prompt 
therapy [132]. 
The standard treatment for seizure emergencies is intravenous administration of 
benzodiazepines, usually lorazepam or diazepam followed by phenytion or fosphenytoin 
[133].  Although intravenous route is the most effective option for quick cessation of 
1 This chapter has been published by Elsevier as: A Pilot Study Assessing the Bioavailability and Pharmacokinetics of 
Diazepam after Intranasal and Intravenous Administration in Healthy Volunteers, Epilepsy Research, (2013) 105, 
362-367. doi: 10.1016/j.eplepsyres.2013.02.018. Reproduction rights for this dissertation granted by the publisher. 
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seizures,  therapy gets delayed as it requires skilled medical personnel and transportation 
to medical facility.  Diazepam rectal gel (Diastat®) is the only formulation of diazepam 
indicated for the out-of-hospital management of selected, refractory patients who require 
intermittent use of diazepam to control bouts of increased seizure activity such as acute 
repetitive seizures.  Introduction of rectal diazepam products in Europe and in the United 
States dramatically changed the management of seizure emergencies.  With these 
formulations, caregivers were able to achieve good outcomes by initiation of early 
treatment after the onset of acute repetitive and prolonged seizures.  As a result, 
emergency department admissions have declined with a decrease in health care costs and 
improved quality of life [134].  Nonetheless, social objections by older children and 
adults and legal concerns about rectal administration have limited its use.  As a result, 
many patients do not realize the benefit of a therapy that can improve outcomes and 
decrease healthcare costs.   Shortly after the introduction of rectal diazepam, a need for 
alternative route of administration was realized and interest emerged to investigate and 
develop different formulations of benzodiazepines (clonazepam, diazepam, lorazepam, 
and midazolam) using one or more routes of administration such as buccal, intramuscular 
and nasal. 
Intranasal benzodiazepines appear to be particularly promising and several research 
groups carried out studies to investigate the pharmacokinetics, bioavailability and 
tolerability [65-73, 75-77].  To meet the need of an alternate therapy for seizure 
emergencies, our group has investigated several intranasal formulations of diazepam.  
Our earlier studies have demonstrated the feasibility of nasal administration of diazepam 
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[68].  Diazepam was absorbed rapidly following nasal administration and the 
pharmacokinetic profile of intranasal formulations compared favorably to that of the 
rectal diazepam gel. However, the tolerability was only moderate.  The results of earlier 
studies concluded that intranasal diazepam offers a viable alternative to rectal 
administration, however further enhancement of formulations was needed to both 
improve tolerability and the extent and consistency of absorption.  In the current study, 
two novel formulations of diazepam nasal spray have been evaluated and compared with 
intravenous administration.  The primary objective of this study was to assess the 
bioavailability and pharmacokinetics (PK) of diazepam after intranasal administration of 
solution and suspension formulations in healthy volunteers under fasted conditions.  The 
secondary objective of this study was to assess the safety and tolerability of these two 
diazepam nasal spray formulations after a single administration. 
3.1.2 Methods 
3.1.2.1 Subjects and Study Design 
Subjects were healthy volunteers 18 to 45 years old with BMI between 19 and 30 kg/m2, 
who provided informed consent and were compensated for participation. Subjects with 
known history of severe seasonal or non-seasonal allergies, having nasal polyps or any 
nasal passage abnormality that could interfere with nasal spray administration were 
excluded.  Subjects who were pregnant or lactating, smoking or using tobacco products 
within the 6 months prior to the first dose of the study drug, allergic to diazepam, or have 
been on restrictive diet were also excluded. The study was approved by the Institutional 
Review Boards at the University of Minnesota and was conducted at PRISM Clinical 
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Research Unit (CRU) in St. Paul, MN.  The principal investigator was present at the CRU 
during and following drug administration. 
The study utilized a randomized, open-label, six sequence, three-way crossover design to 
compare the pharmacokinetics and bioavailability of a commercially available 
parental diazepam (DZP) administered intravenously (5 mg) with two novel intranasal  
DZP  formulations (10 mg). Twenty four subjects received the two intranasal and one 
intravenous dose of DZP with a two-week washout period between doses. Prior to each 
of the three treatments, the subject's eligibility was reviewed. Subjects were instructed to 
abstain from prescription drugs and over the counter medications, 14 days and 7 days 
prior to the first dose of study, respectively.  Treatment with any known enzyme altering 
drugs such as barbiturates, phenothiazines, cimetidine, carbamazepine, within 30 days 
prior to the first dose of study drug or during the study was also one of the exclusion 
criteria.  Subjects were admitted to the study unit no later than 1900 hours of the evening 
prior to study drug administration. The next morning, following an overnight fast, 
subjects were randomized to receive 10 mg intranasal dose of DZP solution, or 10 mg 
intranasal dose of DZP suspension, or 5 mg intravenous dose of DZP.  Subjects fasted for 
an additional 4 hours after the diazepam dose. Water consumption was restricted from 1 
hour prior to dosing until 1 hour postdose.  
3.1.2.2 Study Drugs  
The intravenous formulation used in this study was the commercially available 
parenteral DZP (diazepam injectable, 5 mg/mL, USP).  A single 5 mg diazepam injection 
was given intravenously, over one minute, as directed in the product package insert.  The 
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intranasal DZP formulations were supplied by Neurelis, Inc. The intranasal diazepam 
dose of 10mg  in 0.1mL was administered using the Pfeiffer/Aptar sprayer which is 
commercially available, with the subject lying in the semi-recumbent position.   
3.1.2.3 Drug Assay 
Blood samples (6mL) for the measurement of plasma concentrations of diazepam were 
collected in blood collection tubes containing K2-EDTA at the following times relative to 
dosing:  prior to dosing and at 2.5, 5, 10, 15, 20, 30, and 45 minutes and at 1, 1.5, 2, 4, 8, 
12, 24, 36, 48, 72, 96, 144, 192, and 240 hours from the start of the intravenous infusion 
or after an intranasal dose.   Plasma was separated by centrifugation and frozen at 
approximately -20°C, pending analysis by LC/MS/MS.   
To prepare a sample for analysis, 20 µL of a 10ng/mL Diazepam-d5 solution (internal 
standard) and 0.2 mL of water was added to a 50 µL of K2-EDTA human plasma.  The 
samples were vortexed, extracted using ABN SPE plates, eluted with methanol and taken 
to dryness under nitrogen at approximately 40°C.  The dried residues were reconstituted 
in 200 µL of 1:1 methanol:water.  After one minute of vortex mixing, 15 µL of the 
sample solution was injected onto the LC/MS/MS system.  Standard curves over a range 
of 0.1 ng.mL to 100 ng/mL and quality control DZP samples containing 0.3 (low), 6 
(medium) and 80 ng/mL (high) were prepared.   
3.1.2.4 Pharmacokinetic Analysis 
DZP concentration–time data were analyzed using a non-compartmental pharmacokinetic 
approach with Phoenix software (version 6.2; Pharsight Corporation, Mountain View, 
CA, USA). The terminal rate constant (λz) was determined from the slope of the terminal 
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log-linear portion of the plasma concentration-time curve, and the terminal half-life (T1/2) 
was calculated as ln 2/(λz). Maximum plasma concentrations (Cmax) and time to 
maximum concentration (Tmax) were determined by direct observation of the data. The 
area under the concentration–time (AUC) curve to the last non-zero plasma concentration 
(Clast) that was above the lower limit of quantification (0.1 ng/mL) was calculated as 
AUClast. The area under the concentration–time curve extrapolated to infinity (AUC0–∞) 
was calculated as AUClast + (Clast/λz).  Means and standard deviations for the parameters 
were also obtained using the descriptive statistics tool in Phoenix version 6.2.  
3.1.2.5 Safety Evaluation 
Safety was assessed by adverse event monitoring; clinical laboratory evaluations; 
changes in vital signs measurements, physical examinations, and ECG results.  Nasal 
irritation was evaluated by a trained observer within two (2) hours before and post-dose 
following the one-hour PK sample and the 24-hour PK sample using the following nasal 
irritation scale: 
0 - Normal appearing mucosa, no bleeding 
1 - Inflamed mucosa, no bleeding 
2 - Minor bleeding which stops within 1 minute 
3 - Minor bleeding, taking 1-5 minutes to stop 
4 - Substantial bleeding for 4-60 minutes, does not require medical intervention 
5 - Ulcerated lesions, bleeding which requires medical intervention   
A sedation scale was used to assess the degree of drowsiness of the subjects after 
administration of the intranasal and intravenous diazepam formulations.  Sedation scores 
were reported by the subject (if awake) as well as by a trained observer using the same 
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rating scale, just prior to (baseline) and at 5, 15, 30, 60 minutes and at 2,3,4,6 & 8 hours 
post dose.  The sedation scale used for rating drowsiness consisted of the following 
options: 
0 - Alert, not drowsy; normal conversation 
1 - Awake, talking; but somewhat drowsy 
 2 - Napping or sleeping, but easily awakened 
3 - Sleeping, awakened only with loud voice or shaking 
4 - Sleeping, very difficult to awaken; promptly returns to sleep 
5 - Sleeping, cannot awaken 
3.1.2.6 Statistical Analysis  
Statistical analysis of PK parameters Cmax, AUClast and AUC0-∞ was done after log 
transformation.  Repeated measures ANOVA followed by Tukey’s multiple comparison 
test was used to test for statistical differences in AUC and T1/2 among the intranasal and 
IV formulations.  A paired t test was employed to determine if statistical differences 
existed in Cmax, the maximum observed concentration, between the two intranasal 
formulations.  A Wilcoxon matched-pairs, signed-ranks test was used to test for a 
statistical difference in Tmax, the time to maximum plasma concentration, between the 
two intranasal formulations. 
3.1.3 Results 
All 24 subjects (19 male and 5 female) completed the study.  The mean (±SD) weight of 
the 24 subjects was 78.1 (±11.0) kg.  The age range of subjects was 21 to 45 years, with a 
mean of 32.6 years.   
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A summary of the pharmacokinetic parameters is presented in the Table 3.1-1.  It is to be 
noted that there were 4 subjects each for the suspension and solution treatments for whom 
a valid estimate of λz could not be calculated and thus AUC0-∞ and T½ were not 
calculated either.  This was either due to lack of a log-linear decay, a coefficient of 
determination (r²) < 0.9000, or an extrapolated AUC that was >20% of AUC0-∞.   The 
mean concentration time profiles for all the three arms are shown in the Figure 3.1-1.   
DZP concentrations rose rapidly and were maintained for several hours following 
administration of both intranasal formulations.  The mean intranasal DZP suspension 
Cmax and Tmax were 221 ± 78.6 ng/mL and 1.25 ± 0.5 hours respectively.  The mean 
intranasal DZP solution Cmax and Tmax were 272 ± 100 ng/mL and 1.51 ± 0.88 hours 
respectively.  Median Tmax values for the suspension and solution formulations were 
similar to the mean values: 1hr and 1.5hr, respectively.  Total systemic exposure 
following administration of DZP intranasal solution (absolute bioavailability – 97%) was 
greater than that of the intranasal suspension (absolute bioavailability- 67%).  The mean 
elimination T1/2 was comparable for all three formulations indicating that there was no 
prolonged absorption of diazepam following intranasal administration (Figure 3.1-2).  
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Table 3.1-1. Mean ± SD of DZP pharmacokinetic parameters following intranasal 
(10 mg) and intravenous (5 mg) administration in 24 healthy volunteers. 
Pharmacokinetic 
Parameter a 
10 mg Nasal 
Suspension 
Mean ± SD 
10 mg Nasal 
Solution 
Mean ± SD 
5mg Intravenous 
Mean ± SD 
Cmax (ng/mL) 221 ± 78.6d 272 ± 100 - 
Tmax( hr) b 1.00 [0.6-2.0] 1.50 [0.8-4.0] - 
AUClast  (ng.h/mL) 5229±1463e 7340 ± 1882 3832 ± 1150 
AUC0-∞ c 
(ng.h/mL) 5381 ± 1409
e   7338 ± 2072 4104 ± 1318 
Bioavailability 67 % 97 % - 
T1/2 (hr) c 56.2 ± 23.0 49.2 ± 16.9 56.2 ± 21.0 
a: Mean values are presented as arithmetic means 
b: Median (Min, Max) reported for Tmax 
c: N=20 for Nasal suspension and Nasal Solution.  There were 4 subjects each for the suspension and solution 
treatments for whom a valid estimate of λz could not be calculated and thus AUC0-∞ and T½ were not calculated either.  
This was either due to lack of a log-linear decay, a coefficient of determination (r²) < 0.9000, or an extrapolated AUC 
that was >20% of AUC0-∞.     
d: Two-tailed p value < 0.05 (Paired t-test) 
e: Nasal Suspension vs. IV and Nasal Solution  – p value < 0.05 (Tukey’s multiple comparison test) 
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Figure 3.1-1: Mean (+ standard deviation) Plasma Concentration- time Profiles of 
Diazepam after Intravenous and Intranasal Administration in Twenty-Four 
Subjects (0—12 h). Inset shows the complete profile (0—240 h). 
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Figure 3.1- 2: Mean (+ standard deviation) Plasma Concentration-time Profiles of 
Diazepam after Intravenous and Intranasal Administration in Twenty-Four 
Subjects (Semi-Logarithmic Scale). 
Both investigational intranasal formulations were well tolerated.  Overall, 71% of 
subjects experienced ≥ 1 treatment-emergent adverse effects (AEs) during the study, with 
similar numbers of subjects experiencing AEs after administration of intranasal 
suspension (9 subjects), intranasal solution (8 subjects), and IV diazepam (10 subjects). 
The most commonly reported AEs were epistaxis and somnolence (6 subjects each). 
Mild, self-limited epistaxis  (a few drops of blood in either nostril) was observed 
following administration of IV diazepam (3 subjects, 5 events), intranasal solution (3 
subjects, 3 events) and intranasal suspension (1 subject, 1 event).  Somnolence was more 
frequently associated with IV diazepam (4 subjects) than with either of the intranasal 
diazepam formulations (1 subject each). All treatment-emergent AEs were characterized 
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by the investigator as being mild or moderate in severity.   There were no AE reports of 
nasal pain by any subject in any treatment period. Thirteen subjects experienced AEs that 
were considered by the investigator to be related to intranasal study drug formulations; 
most common AEs were headache, somnolence, epistaxis, and nasal discomfort.  No AE 
met the criteria of a serious adverse event, and none resulted in a subject’s withdrawal 
from the study.  
3.1.4 Discussion 
The absolute bioavailability of intranasal solution approached 100% and was higher than 
that reported in prior intranasal diazepam studies, while variability in exposure (AUC) for 
both the suspension and the solution was similar to the IV dose (Table 3.1-1).  Our results 
compare favorably with studies involving rectal administration of diazepam.  Milligan et 
al. administered a 20 mg rectal DZP solution to 10 epilepsy patients.  The onset of 
reduction in EEG spike counts occurred approximately 15-20 min after drug 
administration and was associated with a plasma DZP concentration of approximately 
200 ng/mL. The 60% reduction in spike counts and DZP concentrations above 200 ng/ml 
were sustained for the duration of the 3 hr observation period [135].  In our current study, 
for both the formulations, the mean Cmax following a 10 mg dose was above the 200 
ng/mL threshold associated with a reduction in spike counts.  Following intranasal 
solution administration, 18 out of 24 subjects attained DZP concentrations above the 200 
ng/mL threshold.  By comparison, following the intranasal suspension administration 15 
out of 24 subjects attained DZP concentrations greater than 200 ng/mL threshold.   
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The intranasal solution formulation had an absorption and elimination profile similar to 
that observed for the commercially available DZP rectal gel (Diastat®) as reported by our 
group.  The absolute bioavailability of the nasal solution was approximately 10% greater 
than that reported for DZP rectal gel (Diastat®), but half-life, Tmax  and dose-adjusted 
Cmax were comparable [136].  In that bioavailability study, we found a mean Cmax of 447 
± 91.1 ng/ml following 15 mg dose of diazepam rectal gel administration.  In the present 
study, the average Cmax for the 10 mg dose of the intranasal solution formulation was 
approximately 270 ng/mL.   Ivaturi et al.  reported a linear increase in Cmax with 
diazepam dose reflecting approximate dose proportionality [68].  Assuming a linear 
increase in Cmax occurs with the intranasal solution of diazepam formulation used in the 
current study, increasing the dose to 15 mg from 10 mg should result in peak 
concentrations in the range of 400 ng/mL.  The mean concentrations for the intranasal 
solution were maintained above100 ng/mL until approximately 8 hours after the drug 
administration.  Assuming linear pharmacokinetics, doubling the dose from 10 mg to 20 
mg will result in concentrations above 200 ng/mL for about 8 hours. 
A critical factor when considering intranasal benzodiazepine therapy for seizure 
emergencies is the time to reach a targeted drug concentration.  As compared to the rectal 
study using the commercially available diazepam rectal gel, the intranasal formulations in 
the present study exhibited a comparable rate of absorption.  In our rectal gel study, we 
reported an initial peak concentration of 375 ng/mL at 45 minutes and a second peak of 
447 ng/mL at 70 minutes.  The intranasal suspension and solutions used in the current 
study attained average peak concentrations at 60 minutes and 90 minutes respectively.   
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One of our key findings was that the variability in exposure (AUC) for both the solution 
and suspension was similar to IV dose (coefficient of variation, 30%). The rectal gel 
study reported an absolute bioavailability of approximately 90%.  Simulations are needed 
to determine the sample size required to show bioequivalence between the rectal gel and 
the intranasal solution.  Our study was intended to serve as a pilot study to provide 
information on the suitability of one or both formulations for further development.  The 
information gained from this study can be used to design future, adequately powered 
bioavailability and bioequivalence studies. 
Prior studies with diazepam and midazolam reported dual peaks reflecting oral absorption 
in which the first peak representing nasal absorption occurs within 20-30 minutes and a 
second peak presumably due to enteral absorption occurs around 1-2 hours after drug 
administration.  In some of the studies reporting dual peaks, subjects actually commented 
that they swallowed a portion of dose administered intranasally.  Second diazepam peak 
concentrations were not observed in our current study results.   
Our earlier studies with a glycofurol based intranasal formulation of diazepam resulted in 
75 % & 74 % bioavailability after administration of 5 and 10 mg DZP doses, respectively 
[68]. The formulations were absorbed rapidly but the tolerability was poor which made it 
unsuitable for further development.  Subsequently, two other intranasal formulations 
compared the pharmacokinetics and tolerability with rectal diazepam gel.  In that study, 
the pharmacokinetics profile of the two investigational diazepam formulations was 
comparable to that of rectal diazepam gel.   No serious adverse effects were reported 
following administration of intranasal formulations; however, majority of the subjects 
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reported nasal discomfort or pain immediately after dose administration.  In this current 
study, both diazepam nasal spray formulations were remarkably well-tolerated. There 
were no AE reports of nasal pain by any subject in any treatment period.   It is 
noteworthy that intranasal administration of diazepam did not appear to cause epistaxis - 
more epistaxis events were reported following IV diazepam than after administration of 
either intranasal formulation.  Nasal drug delivery can cause epistaxis and other nasal 
diazepam formulations may carry this risk, but the most plausible explanation for 
epistaxis in our study following IV administration is that individuals occasionally 
experience minor nose bleeds in harsh winters with dry interior environment.The nasal 
DZP solution shows promise as a socially acceptable, well-tolerated, easily administered 
formulation for use in seizure emergencies.  Its pharmacokinetic profile is similar to 
rectally administered diazepam with high bioavailability, reasonable variability, and rapid 
attainment and maintenance of therapeutic drug concentrations.  The absolute 
bioavailability of the intranasal solution was approximately 100% and was higher than 
that reported in prior intranasal diazepam studies. Variability in exposure (AUC) for both 
the suspension and solution was similar to the IV dose.   The results of this pilot study 
indicate that development of an intranasal diazepam formulation with high 
bioavailability, reasonable variability, and good tolerability is feasible. 
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 3.2 Application of Modeling and Simulation to Optimize a Bioequivalence Trial of 
Nasal and Rectal Diazepam 
3.2.1 Introduction 
Our research group has conducted several Phase-I clinical studies of diazepam comparing 
pharmacokinetics and tolerability of intravenous (IV), rectal and nasal (IN) formulations.  
The intranasal phase-I clinical data were generated from five different diazepam 
formulations.  The glycofurol-based supersaturated formulation caused moderate 
irritability and was not tolerated well by subjects.  Two other formulations which were 
microemulsion-based, showed low bioavailability.  Results from a most recent 
pharmacokinetic study investigating two other IN formulations (NRL.1.A and NRL.1.B) 
have shown high bioavailability and good tolerability.  Therefore, among the five IN 
formulations, NRL.1.A and NRL.1.B are being considered for further development.   
Developmental Pathway for Intranasal Diazepam 
There are two possible development paths for the potential approval of a nasal diazepam 
product.  One pathway would be the traditional development route of having to prove 
safety and efficacy in at least one or more placebo controlled clinical trials after 
establishing the pharmacokinetics and toxicity over a range of doses.  The other, possibly 
quicker pathway, would be to use either 505 (b) (2) or 505 (j) of the Hatch-Waxman act 
(see below).   
Section 505 (b) (2): Drug products that may be submitted under section 505(b) (2) are 
not completely new products, yet they are not generics. These medications have both 
similarities and some differences from an innovator or brand drug. In the case of 
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intranasal diazepam the product has the same active ingredient as the previously 
approved rectal diazepam product, but now is formulated in a different delivery 
mechanism and a different route of administration.  
The basis for the 505(b) (2) application is that there already is a certain amount of 
information that is known about the active ingredient.  Under the rules in section 505(b) 
(2), the applicant can rely on information from studies it did not conduct and for which it 
does not have the raw data to base its conclusions (right of reference). The implication of 
this section for development of intranasal diazepam would be that the sponsor may rely 
on efficacy performance of rectal diazepam and conduct only pharmacokinetic and safety 
studies for intranasal diazepam. This would save both valuable time and resources for a 
sponsor. 
Section 505 (j): Section 505 (j) refers to the generic drug approval process also 
commonly known as the Abbreviated New Drug Approval (ANDA) application. For an 
ANDA, the sponsor only needs to complete studies that demonstrate that the generic 
product is bioequivalent to the innovator product.  
Thus, for intranasal diazepam, 505(b) (2) path may be chosen under which the sponsor 
may rely on efficacy performance of rectal diazepam and conduct only pharmacokinetic 
and safety studies for intranasal diazepam.  Under this pathway, the sponsor will need to 
conduct a Phase I study to compare the pharmacokinetics of intranasal and rectal 
diazepam.  Although not necessary for approval, it would be ideal if the sponsor could 
show that the intranasal product is bioequivalent to rectal diazepam.  Typically 
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bioequivalence trials are done in 24-36 healthy volunteers. In the same study or a 
separate study, escalating doses of the intranasal formulation must be investigated to 
demonstrate linear pharmacokinetics and safety with increasing dose.   
This project was aimed to develop a PK model, using data from current work and five 
previously conducted studies, which will be useful in designing a future bioequivalence 
study of rectal and intranasal diazepam.   
Objectives 
1. To characterize the pharmacokinetic parameters of different formulations of 
diazepam (IV, IN, and rectal) using a non-linear mixed effects modeling approach. 
2. To test the hypothesis that the IN solution (NRL.1.B) will produce a similar 
exposure as that observed following rectal administration. 
3.2.2 Methods 
3.2.2.1 Study Design 
All studies were conducted with the approval of the local Institutional Review Boards.  
Concentration-time profiles from 99 subjects in six Phase I studies of IV, IN and rectal 
diazepam comprised the final population PK database.  Study design information, 
including subject populations, formulations, doses and PK sampling are given in Table 
3.2-1.  It is to be noted that extravascular pharmacokinetic data following single doses of 
two intranasal formulations (NRL.1A and NRL.1B) and the commercially available rectal 
diazepam gel (Diastat®) formulations were included in the database.  All plasma samples 
with quantifiable concentrations of diazepam were used for the population 
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pharmacokinetic model development.  Measurements below the limit of quantification 
and missing values were excluded from the analysis.   
Table 3.2- 1. Description of studies included in the diazepam population 
pharmacokinetics database 
Study Design Subjects PK 
Sampling 
Doses Formulation 
S01 Single blind, 
single dose 
phase 1 
Females (n=3) 0-48 h IV – 5mg IV-Valium® 
S02  Single blind, 
single dose, 
phase 1 
Males (n=6) 
Females (n=2) 
0-48 h IV – 5mg 
S03 Open label, 
single dose, 
phase 1 
Males (n=9) 
Females (n=3) 
0-240 h Rectal – 10 
mg 
Rectal - 
Diastat® 
L01 
 
Single blind, 
2 way 
crossover, 
phase 1 
Males (n=18) 0-240 h IV – 7.5 mg 
Rectal – 15 
mg 
IV-Valium® 
L02 Single blind, 
3 way 
crossover, 
phase 4 
Males (n=18) 
Females (n=16) 
0-240 h Rectal – 15 
mg, in 3 
periods 
Rectal -
Diastat® 
S04 Single blind, 
3 way 
crossover, 
phase 1 
Males (n= 19) 
Females (n = 5) 
0-240 h IV – 5 mg 
IN – 10 mg 
 
IV - 
Diazepam 
USP 
IN - NRL.1.A 
& NRL.1.B  
3.2.2.2  Data Analysis 
The population PK analysis was conducted via non-linear mixed-effects modeling in 
NONMEM (version - 7) software using PDxPOP version 5 for pre- and post-processing.  
The first-order conditional estimation method with eta-epsilon interaction (FOCE) was 
used for all model runs.  Selection of models was guided by the likelihood ratio test (χ2, 
P<0.05), diagnostic plots, physiological plausibility and precision of parameter estimates.  
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Final model parameter estimates were reported with a measure of estimation uncertainty 
based on the nonparametric bootstrap 95% confidence intervals. 
Structural Model 
Concentration-time profiles of IV, IN and rectal diazepam were simultaneously fit to 
various PK models.  A sequence of compartmental models was tested and the results 
compared.  An open two-compartment pharmacokinetic model with the first-order 
absorption and elimination was finally chosen for model fitting and was implemented 
with ADVAN4 and TRANS4 subroutines.  The bioavailability (F) and first-order 
absorption rate constant (Ka) were estimated separately for each rectal and intranasal 
formulation. 
Statistical Model 
Between-subject variability (BSV) was estimated using an exponential error model, or 
log-normal parameter distribution (Equation 1) that expresses population variability as a 
coefficient of variation.   
βi = * exp (ηPi)…………………………….Equation 1 
Where, βi is the estimated parameter value for individual i, is the typical population 
value (geometric mean) of the parameter, and ηPi  is the individual-specific 
interindividual random effects for subject i and parameter β.  These random effects are 
assumed to be normally distributed with a mean of zero and variance of ω2; η ~ N (0, ω2).   
Interindividual variability was included on clearance (CL), central volume of distribution 
(V2), intercompartmental clearance (Q), peripheral volume of distribution (V3), 
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absorption rate constants (Ka)  and bioavailability (F) for rectal and two intranasal 
formulations.  Residual variability was accounted for using a proportional error model 
(Equation 2). 
Cij(obs) = Cij(pred) + Cij(pred)* εij…………………………….Equation 2 
where, Cij(obs) and Cij(pred) are the observed and predicted diazepam values in the ith 
individual at the jth time point respectively, and εij are random effects which are assumed 
to be normally distributed with a mean of zero and variance of σ2;  εij ~N(0, σ2). 
Model-Based Simulation Studies 
To test the hypothesis that one of the investigational intranasal product will produce a 
similar exposure as is obtained following rectal administration, model-based simulation 
studies were performed.  The final PK model was used to simulate 100 trials with 24 
subjects in a two-way crossover design comparing an IN dose of 8 mg from the NRL.1B 
formulation and a dose of 10 mg of the rectal product.  Doses for simulation were 
decided based on the mean absolute bioavailability estimates obtained from the 
population PK model.  Concentrations were simulated at 0, 2.5, 5, 10, 15, 20, 30, and 45 
minutes and at 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 192, and 240 hours.   Area under 
the curve (AUC0-inf) was derived using two methods.  In the model-based approach, 
AUCs were calculated by dividing the dose by simulated individual clearances from 100 
simulations.  In the traditional NCA approach, AUCs were calculated using the 
trapezoidal area formula on each of the simulated concentration-time profiles within 100 
simulations.  The AUCs calculated from model-based approach, do not take into account 
the residual variability which represents model misspecification and assay variability.   
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For each of the simulated trials, the 90% CI of the geometric mean for the AUC ratio 
(IN/rectal) was computed in Phoenix (version 6.2), and the results were compared to the 
standard bioequivalence limit of 80–125%.  Two products would be considered to result 
in similar systemic exposure if the 90% CIs of the geometric mean AUC ratios (IN/rectal) 
fell within the bioequivalence limits of 80–125%. 
Model Evaluation 
The final population PK model was evaluated using a predictive check and a 
nonparametric bootstrap.    For the predictive check, 100 Monte Carlo simulation 
replicates of the original data set were generated using the final population PK model, 
and the distribution of the median concentration (Cmed) in the simulated data was 
compared with the distribution of the same characteristic in the observed data using 
exploratory graphics.  For the nonparametric bootstrap procedure, 1000 replicate data sets 
were generated by random resampling from the original data set with replacement, using 
the individual as the sampling unit.  Population parameters for each data set were 
subsequently estimated using NONMEM, and empirical 95% CIs were constructed by 
observing the 2.5th and 97.5th quantiles of the resulting parameter distributions for all 
bootstrap runs. 
3.2.3 Results 
Subject Demographics 
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Subject demographics are summarized in Table 3.2-2.  The age of subjects ranged from 
19 to 64 years, with a mean (SD) of 32.4 (9.6) years. The mean (SD) weight was 72.5 
(14.0) kg.   
Table 3.2- 2. Summary of subject demographics in the population pharmacokinetic 
database  
Categorical Covariate 
 No. of Subjects Percent 
Sex 
 Male 
 Female 
 
70 
29 
 
70.7 
29.3 
Continuous Covariates 
 Mean ± SD Range 
Weight (Kg) 72.5 ± 14 45-115 
Age (Years) 32.4 ± 9.6 19-64 
 
Population PK Model 
There were 24 subjects who received both IV and IN diazepam, 46 received only rectal, 
18 received both rectal and IV formulations, and 11 received only IV diazepam; these 
subjects contributed to a total of 53 IV profiles, 48 IN profiles and 132 rectal profiles.  
Diazepam pharmacokinetics were best described by an open two-compartment 
pharmacokinetic base model with first-order absorption and elimination.  This model was 
implemented in NONMEM using ADVAN4 and TRANS4 subroutines.   
Table 3.2-3 provides the parameter estimates of the structural and random variance 
parameters from the final model.    The final model included a two compartment model 
with interindividual variability on clearance (CL), central volume of distribution (V2), 
intercompartmental clearance (Q), peripheral volume of distribution (V3), absorption rate 
constants (Ka)  and bioavailability (F).   
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Table 3.2- 3. Population pharmacokinetic parameters for the typical individual after 
intravenous, rectal or nasal administration of diazepam 
Parameter NONMEM analysis Bootstrap analysis 
Estimate (% 
RSE) 
95% C.I. Median 
Estimat
e 
95th 
percentile 
Structural Model: 
CL(L/hr) 1.26 (3.94) 1.16 – 1.36 1.26 1.16 – 1.37 
Vc (L) 17.9 (7.65) 15.2 – 20.6 17.9 15.8 – 20.5 
Q (L/hr) 11.3 (7.4) 9.66 – 12.9 11.38 9.74 – 12.86 
Vp (L) 58.4 (5.5) 52.1 – 64.7 58.72 53.5 – 68.8  
Rectal Ka (1/hr) 1.29 ( 12.8) 0.967 – 1.61 1.29 1.01 – 1.58 
Rectal F  0.798 (3.27) 0.747 – 0.849 0.80 0.74 – 0.86 
IN (NRL.1.A) Ka 
(1/hr) 
0.505 (12.0) 0.386 – 0.624 0.50 0.39 – 0.65 
IN (NRL.1.A) F 0.706 (3.71) 0.655 – 0.757 0.70 0.65 – 0.75 
IN (NRL.1.B) Ka 
(1/hr) 
0.406 (13.8) 0.296 – 0.516 0.40 0.30 – 0.53 
IN (NRL.1.B) F 0.991 (4.26) 0.908 – 1.07 0.99 0.91 – 1.06 
Error Model:  % CV (%RSE) 95% C.I.  
IIV of CL 29.4(19.7) 23.06 – 34.6  28.98 23.95 – 34.35  
IIV of Vc  33.9 (24.7) 24.35 – 41.35 33.72 26.04 – 43.64 
IIV of Q 48.6 (28.7) 32.09 – 60.75 48.21 34.85 – 60.15 
IIV of Vp  40.9 (17.0) 33.32 – 47.22 40.80 34.16 – 47.28 
IIV of Rectal Ka  59.0 (32.2) 35.78 – 75.37 58.07 38.77 – 77.81 
IIV of Rectal F  22.2 (29.3) 14.49 – 27.82 21.91 14.66 – 26.9 
IIV of Ka (NRL.1.A) 53.5 (38.8) 26.15 – 70.99 52.19 31.38 – 74.42 
IIV of F (NRL.1.A) 11.2 (56.3) 0 –16.28 10.95 3.18 – 15.95 
IIV of Ka (NRL.1.B) 63.2 (24.5) 45.61 – 76.94 61.82 43.80 – 78.22 
IIV of F (NRL.1.B) 16.2 (50.2) 2.07 – 22.85 15.97 3.15 – 22.53 
RUV, Proportional 28.6 (9.08) 25.94 – 31.06 28.65 27.21 – 29.97 
IIV – Interindividual variability                            
RUV – Residual unexplained variability 
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Diagnostic plots of the observed and population model predicted concentrations after 
intravenous, rectal and nasal administrations stratified by formulation are shown in 
Figure 3.2-1.  Goodness-of-fit diagnostic plots for structural and error model are shown 
in Figure 3.2-2.   
Estimates for the structural and random variance parameters demonstrated good precision 
with the exception of the inter-individual variability estimates of the absorption rate 
parameters (Ka).  The bioavailability of the intranasal solution (NRL.1.B) approached 
100% with a 95% confidence interval of 90% – 107%.  In contrast, the bioavailability of 
the rectal product was estimated to be 80% with a 95% confidence interval of 75% to 
85%.   
  
 
Figure 3.2- 1 (a): Model-based population predicted and individual predicted versus 
observed diazepam concentrations after intranasal administration of the two 
different formulations. Left Panel: Suspension Formulation. Right Panel: Solution 
Formulation 
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Figure 3.2-1 (b): Model-based population predicted and individual predicted versus 
observed diazepam concentrations after intravenous (Left) and rectal (Right) 
administration  
 
 
  
 
Figure 3.2- 2: Conditional weighted residuals vs population predicted diazepam 
concentration (ng/mL and vs time (h).  Values are indicated by solid blue dots with a 
smoothing spline trend line through the data.  A dashed line at y=0 is included as a 
reference. 
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Model Evaluation 
 
The intranasal and rectal population PK model evaluation was carried out by predictive 
check and a nonparametric bootstrap procedure.  Results reveal that the final model 
provided a reliable description of the data with good precision of structural model and 
most of the variance parameter estimates.  The predictive check demonstrated that the 
simulated distributions of Cmed values were in agreement with observed values (Figure 
3.2-3), except for rectal administration.  For rectal administration, the 5th percentile for 
observed concentrations was higher than the 90% CI of corresponding simulated 
concentrations for time points ≥ 150 hours.  The lower limit of quantification (LLOQ) in 
all the rectal studies (Study S03, L01, and L02) was 2 ng/mL, whereas it was 0.1 ng/mL 
in the intranasal study (Study S04).  As concentrations below LLOQ were excluded from 
analysis, the 5th percentile for observed concentrations was higher than simulated 
concentrations due to exclusion of concentrations values below 2 ng/mL in rectal studies.    
The non-parametric bootstrap procedure resulted in 95% CIs for population PK 
parameter estimates, which are presented in the final model parameter table (Table 3.2-
3).  Overall, a typical structural model parameters and random variance terms were 
estimated with good precision, with the exception of absorption rate constant parameters. 
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            Rectal Intravenous 
 
 
         Nasal Suspension (NRL.1A) Nasal Solution (NRL.1B) 
  
Figure 3.2- 3: Formulation and route stratified visual predictive check plots for 
diazepam concentrations over time.  The solid line represents the median and the 
dotted line represents the 5th and 95th percentile for observed concentrations.  The 
red band represents 90% CI of the median for model simulated concentrations. 
Blue bands denote 90% CI of the 5th and 95th percentile for model simulated 
concentrations.  
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Simulation Study Results 
 
An 8 mg dose of IN diazepam (NRL.1.B. formulation) was selected to test the hypothesis 
that the investigational intranasal product will produce a similar exposure obtained 
following 10 mg rectal dose.  Model-based calculated AUCs showed that in 88 out of 100 
trials the 90% confidence intervals of the geometric mean intranasal/rectal (or 
test/reference) AUC ratios fell within the bioequivalence limits of 80–125%. Traditional 
NCA showed that in 77 out of 100 trials the 90% confidence intervals of the geometric 
mean intranasal/rectal (or test/reference) AUC ratios fell within the bioequivalence limits 
of 80–125%.  None of the trials met bioequivalence criteria for Cmax. 
Such discrepancy in the rates of success between the two approaches is expected.  Model-
based AUCs does not take into account the residual unexplained variability (RUV) 
whereas the traditional NCA approach does.  The incorporation of the RUV (%CV 
28.6%) in the traditional NCA approach resulted in wider CIs and therefore lower rates of 
success than the model-based analyses.  Though the model-based approach showed high 
success rates, FDA only uses the traditional NCA approach to determine if two products 
are bioequivalent.  Using the traditional approach, 23 out of 100 times, the 90% 
confidence intervals for the geometric mean nasal/rectal ratios of AUCs were out of the 
80-125% limits (see Figure 3.2-4).   
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Figure 3.2- 4: Scatter plot of Geometric mean ratios (Nasal/Rectal) of AUCs and 
90% CI for 100 simulations 
3.2.4 Discussion 
A two-compartment model with four parameters (CL, Q, Vc and Vp) best described the 
disposition of diazepam.  Two additional parameters (Ka and F) were estimated per 
formulation to characterize the absorption phase.  Model structural parameters and 
random variance parameters were estimated with good precision.  Goodness-of-fit plots 
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revealed that the model described the observed data well.  The parameter estimates for 
the fixed and random effects from the bootstrap procedure are comparable and within 5-
10% of the estimates from NONMEM, indicating that the final model is robust [137].  
To better characterize the absorption phase of data, we implemented more complex 
absorption models.  These include transit compartmental model and Erlang frequency 
distribution, which describes asymmetric s-shaped absorption profiles.  However, there 
was not a significant improvement seen with these complex models and therefore we 
chose to select the simpler first-order absorption model to characterize the absorption 
phase.   
To demonstrate the utility of the developed PK model, we performed simulation studies 
to help designing a future bioequivalence trial.  To prove bioequivalence, the sponsor has 
to show that the 90% confidence intervals of the geometric mean intranasal/rectal (or 
test/reference) of Cmax and AUC ratios fall within the bioequivalence limits of 80–
125%.  77 out of 100 trials showed that total exposure from 8 mg of investigational 
intranasal product (NRL.1.B) and 10 mg of rectal product would pass bioequivalence 
limits.  Although it would be ideal to prove that the intranasal product is bioequivalent to 
rectal diazepam, it is not necessary for approval.  As the bioavailability of intranasal 
formulation (NRL.1B) is higher than rectal product, a 10 mg IN dose of diazepam 
produces greater exposure than a similar dose of rectal diazepam.  However, given the 
bioavailability of oral diazepam approaches 100% and that the safety of a 10 mg dose of 
oral diazepam is well established, a three way Phase I bioavailability and safety study is 
proposed.   If IN diazepam has greater bioavailability than rectal diazepam, but is 
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comparable to oral diazepam; then safety is established. A slightly greater exposure of 
diazepam following IN versus rectal will likely improve efficacy without affecting safety.  
In the same study or a different study, escalating doses of the intranasal formulation must 
be investigated to demonstrate linear pharmacokinetics and safety with increasing dose.   
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 3.3 Characterization of Diazepam Absorption Profiles following Rectal and 
Intranasal Administration using Deconvolution Methods 
 
3.3.1 Introduction 
 
Both the intranasal formulations investigated in the pilot PK study exhibited comparable 
times to average peak concentration with those reported for the rectal formulation (60-90 
minutes vs. 70 minutes, respectively); however, there were significant differences in drug 
concentrations achieved by these two formulations within the first hour.   This was 
apparently due to differences in the rate of absorption in the first hour.   
Milligan et al. rectally administered a 20 mg dose of diazepam solution or placebo to 10 
adults with epilepsy and then observed spike wave activity and measured plasma 
concentrations.  The onset of reduction in EEG spike counts occurred approximately 15-20 
min after drug administration and was associated with a plasma DZP concentration of 
approximately 200 ng/mL [135].  This work demonstrated the exposure-response relationship 
for seizure control with diazepam level of 200 ng/mL, when given rectally.  When 
developing the intranasal formulation, we would like to attain diazepam levels of > 200 
ng/mL within minutes of dosing to quickly terminate seizures and avoid potential brain 
damage caused by seizures.  Therefore, it is important to rigorously evaluate the times to 
attain target concentrations (> 200ng/ mL) of diazepam following rectal and nasal 
formulations.    
Deconvolution can be used to evaluate in vivo drug release from a formulation such as 
oral tablets and the drug input rate following extravascular administration.  Several 
deconvolution algorithms have been published in the literature [138-143].  Deconvolution 
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methods are based on the same assumptions as the AUC method (i.e. linearity and time 
invariance), but have certain advantages.  Once an assumption regarding the 
concentration profile following an intravenous dose is made, the rate of drug input into 
the observation compartment and the cumulative amount absorbed can be calculated. 
Typically non-compartmental analysis techniques are used to calculate the absolute 
bioavailability of an extravascular formulation.  It is calculated as the ratio of the dose-
normalized areas under the plasma concentration-time curves from time zero to infinity 
(AUC0-inf) following extravascular and IV administration.  This method necessitates that 
plasma samples be collected for long time periods (up to 4-5 drug half-lives) to minimize 
percent extrapolation of area under the curve from last collection time point (AUClast) to 
infinity.  In contrast, when using deconvolution, plasma sampling is only needed until the 
drug absorption is completed, which may be only a few hours following drug 
administration [143, 144].  The deconvolution technique makes it possible to evaluate 
both rate of absorption and bioavailability, but does not require collection of plasma 
samples up to 4-5 drug half-lives.  It offers the capability to examine complex absorption 
patterns that may be difficult to evaluate using conventional first-order absorption 
models.   
3.3.2 Methods 
The convolution principle may be expressed as follows: 
C(t) =   C(δ) * f(t)…………………………………………………Equation 1 
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The response function, C(t), is obtained by the convolution of the unit impulse function, 
C(δ), with the input function, f(t).  Mathematical convolution has been functionally 
expressed here by the asterisk.  
Under conditions of linearity and time invariance, the transport of drug from a site i to a 
site j can be completely expressed by the three functions in eq. 1.  C(t) refers to the 
concentration profile obtained when the drug is placed at site i and the concentrations 
measured at site j.  C(δ) refers to the concentration profile at site j obtained after the drug 
is placed directly at site j, and f(t) represents the transfer function that governs the 
movement of mass from site i to j. The knowledge of any two of these three functions 
allows a determination of the third [145]. 
Deconvolution is the mathematical inverse of convolution. This refers to the situation 
where a knowledge of C(t) and C(δ) is used to obtain the input function, f(t). In the 
present work, C(t) is the concentration-time data following rectal and nasal 
administration, C(δ) is derived from the concentration-time data following intravenous 
administration and f(t) is the rate of absorption following nasal and rectal administration. 
The deconvolution procedure included in Phoenix® WinNonlin® 6.2 was performed to 
obtain in vivo input rate or absorption rate profiles of diazepam from both rectal and two 
intranasal formulations.  Data from study S04 and L01 were used (Table: 3.2-1).  In study 
S04, 24 healthy volunteers received diazepam intravenously and nasally from a 
suspension and solution formulation in a three-way crossover design.  Study L01 was a 
two-way crossover study in 18 healthy volunteers who received diazepam intravenously 
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and rectally.  A tri-exponential expression (3-compartment open model) was fitted to the 
plasma concentrations obtained from intravenous administration to obtain individual 
parameter estimates.  The individual parameter estimates were used to obtain unit 
impulse response function (C(δ)). Concentration-time data from nasal and rectal 
administrations were used as the response function (C(t)).  Deconvolution was performed 
using these two functions to calculate input function, f(t).  The deconvolution results are 
expressed as profiles of the input rate over time as well as cumulative fraction absorbed.  
The extent of absorption from both nasal formulations was compared to that of rectal 
administration from time zero to 15, 30, 45 minutes and 1, 1.5, 2, 3, 4,6,8,10,12 hours 
using a t-test to explore the pattern of statistical differences in amount absorbed at early 
time points in the concentration-time profile.  In addition, the estimated extent of 
absorption within 2, 6 and 12 hours was compared for each formulation with the 
bioavailability calculated, based on the traditional NCA approach, using non-parametric 
ANOVA followed by a Dunn’s multiple comparison test. 
3.3.3 Results 
The dose-normalized mean concentration time profiles for all three arms (nasal suspension, 
nasal solution and rectal gel) are shown in the Figure 3.3-1.  Diazepam concentrations rise 
immediately following both nasal and rectal administration.  However, the rate of absorption 
following rectal administration is faster than the two nasal formulations. 
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Figure 3.3- 1: Dose-normalized mean (+ standard deviation) plasma concentration- 
time profiles of diazepam after rectal and intranasal administration in healthy 
subjects (0—2 h).  
 
Absorption rates of diazepam following intranasal and rectal administration were 
determined from the corresponding plasma profiles using deconvolution.  Individual 
disposition parameters were obtained from the corresponding intravenous concentration- 
time profiles.  Input rate or absorption rate profiles of diazepam from nasal and rectal 
administration as a function of time are shown in Figure 3.3-2(a-c). 
Mean 
Conc.  
(ng/mL) 
Time (hr) 
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Figure 3.3-2.a: Input rate profiles of diazepam following administration of 
intranasal suspension in 24 healthy volunteers 
 
Figure 3.3-2.b: Input rate profiles of diazepam following administration of 
intranasal solution in 24 healthy volunteers 
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Figure 3.3-2.c: Input rate profiles of diazepam following rectal administration in 18 
healthy volunteers 
Table 3.3-1 and Figure 3.3-3  show average cumulative fraction absorbed at various time 
points following drug administration using nasal suspension, nasal solution and rectal gel.  
At a significance level of 0.05, extent of absorption following nasal suspension is 
different from rectal gel at all the time points.  This result is not surprising given that both 
the rate and extent of absorption of nasal suspension is lower than rectal gel. In contrast, 
for nasal solution, the extent of absorption was different only at 15 and 30 minutes post-
dose.  At and after 45 minutes, the extent of absorption was similar for both the nasal 
solution and rectal gel.  These differences in the early time periods could be explained by 
differences in the rates and extent of absorption.  
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Figure 3.3- 3: Comparison of extent of absorption for diazepam at different time 
points 
Table 3.3- 1. Comparison of extent of absorption for diazepam at different time 
points 
Time (Hours) Cumulative Fraction Absorbed (Mean ± SD) 
 Nasal Suspension Nasal Solution Rectal Gel 
0.25 0.06 ± 0.09* 0.05 ± 0.06* 0.23 ± 0.11  
0.5 0.21 ± 0.31* 0.20 ± 0.27* 0.41 ± 0.16 
0.75 0.32 ± 0.36* 0.35 ± 0.41 0.55 ± 0.16 
1.0 0.42 ± 0.34* 0.47 ± 0.41 0.64 ± 0.15 
1.5 0.57 ± 0.30* 0.69 ± 0.37 0.79 ± 0.18 
2.0 0.61 ± 0.29* 0.79 ± 0.37 0.89 ± 0.22 
3.0 0.65 ± 0.29* 0.87 ± 0.35 0.92 ± 0.24 
4.0 0.66 ± 0.29* 0.91 ± 0.33 0.92 ± 0.24 
6.0 0.69 ± 0.28* 0.97 ± 0.31 0.95 ± 0.25 
8.0 0.72 ± 0.28* 1.01 ± 0.32 0.96 ± 0.26 
10.0 0.74 ± 0.28* 1.04 ± 0.33 0.96 ± 0.26 
Time (Hours) 
Fraction of 
Drug 
Absorbed 
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12.0 0.75 ± 0.28* 1.05 ± 0.33 0.96 ± 0.26 
*t-test p-value comparing rectal gel <0.05 
Eighteen out of 24 subjects attained diazepam concentrations above the 200 ng/mL 
threshold following intranasal solution.  By comparison, following the intranasal 
suspension administration 15 out of 24 subjects attained diazepam concentrations greater 
than 200 ng/mL threshold. In contrast, dose-normalized concentrations following rectal 
administration revealed that all 18 subjects attained diazepam concentrations above 200 
ng/mL.   
 
 
Figure 3.3- 4: Plot showing percentage of healthy subjects attaining concentrations 
greater than 200 ng/mL over time following rectal and nasal administration 
 
The time to attain threshold concentrations for nasal formulations was considerably 
longer than rectal gel (Figure 3.3-4) in most subjects.   There was significant difference 
between rectal and nasal formulations in the proportion of subjects attaining the threshold 
concentrations of 200 ng/mL in the first 30 and 60 minutes (Fisher’s exact test p value < 
0.05).  Fewer subjects, < 20% and < 60%, achieved concentrations above 200 ng/mL by 
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30 minutes and 1 hour time points, respectively, following nasal solution compared to 
rectal group (~55% and 90%).   It could be argued that this delay in attaining threshold 
concentrations could be overcome by increasing the dose but this approach would need  
to be demonstrated in a future PK study. 
The bioavailability estimated by the traditional NCA approach was compared to the 
cumulative fraction absorbed (at 2, 6 and 12 hours) obtained from deconvolution results.  
The results are shown in Table 3.3-2 and Figure 3.3-5.  It can be inferred from Table 3.3-
2 that the extent of absorption at 2 and 6 hours (column II and III) was smaller than 
thebioavailability calculated from NCA for all the three formulations.  However, there 
was no difference in the extent of absorption at 12 hours (column IV) and bioavailability 
calculated from NCA (column I). 
 
 
 
Figure 3.3- 5: Comparison of extent of absorption for diazepam using NCA and 
Deconvolution at 2, 6 and 12 hours 
Fraction of Drug Absorbed 
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Table 3.3- 2. Comparison of extent of absorption for diazepam using NCA and 
Deconvolution.  Column I shows the bioavailability calculated by NCA and Column 
II, III and IV show the extent of absorption at 2, 6, and 12 hours obtained by 
deconvolution 
Route / 
Formulation 
Bioavailability 
(NCA 
Approach) 
 
(I) 
Mean±SD 
 
Cumulative 
Fraction 
Absorbed at 2 
hours 
(II) 
Mean±SD 
 
Cumulative 
Fraction 
Absorbed at 6 
hours 
(III) 
Mean±SD 
Cumulative 
Fraction 
Absorbed at 
12 hours 
(IV) 
Mean±SD 
Nasal 
Suspension 
0.70 ± 0.12 0.61 ± 0.29* 0.69 ± 0.28* 0.75 ± 0.28 
Nasal Solution 0.98 ± 0.17 0.79 ± 0.37* 0.97 ± 0.31* 1.05 ± 0.33 
Rectal Gel 0.9 ± 0.09 0.89 ± 0.22* 0.95 ± 0.25* 0.96 ± 0.26 
* Dunn’s multiple comparison test comparing column (I): p-value <0.05  
3.3.4 Discussion 
The results from deconvolution analysis were comparable to those of non-compartmental 
approach (NCA).  The mean absolute bioavailability calculated using NCA for all the 
three formulations (rectal, IN solution, and IN suspension) was similar to cumulative 
fraction of drug absorbed calculated by deconvolution.  Both NCA and deconvolution 
techniques do not require any absorption model assumptions; however, input rates or 
absorption rates can be obtained from deconvolution but not from NCA. In contrast, the 
population PK model developed and presented in chapter 3.2 assumed a first-order 
absorption model.  The first-order absorption assumption works well in most of the cases 
but does not allow for secondary peaks resulting from delayed absorption or complex 
absorption mechanisms.  The first-order absorption model assumes that drug absorption 
is governed by a first-order rate constant which only allows for a monotonic function.  On 
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the other hand, deconvolution makes it possible to explore presence of secondary peaks 
and any complex absorption patterns which are otherwise not possible by conventional 
first-order absorption assumption.  
Graphical analysis of input rates following both nasal formulations and rectal gel 
revealed that there was considerable variation in input rates between individuals.  
Following rectal administration, there was greater variability compared to nasal 
administrations.  A second peak between 30 to 90 minutes after dose administration was 
seen in the input rate profiles of most individuals receiving rectal gel.  Secondary peaks 
were observed in only two subjects after intranasal administration. Secondary peaks in 
the input rate profiles suggest delayed absorption but they could also be due to sensitivity 
of deconvolution to errors in the input response data.  Prior studies with intranasal 
benzodiazepines reported double peaks in concentration-time profiles in which the first 
peak representing nasal absorption occurs within 20-30 minutes and a second peak 
presumably due to enteral absorption occurs around 1-2 hours after drug administration.   
In some studies, subjects actually commented that they swallowed a portion of 
administered intranasally dose [68].    While second diazepam peak concentrations were 
not observed in our current study of the two intranasal formulations, this does not 
necessarily rule out the possibility for enteral absorption.   
3.3.5 Conclusions 
Deconvolution results indicate that the absorption rates and patterns are different when 
the drug is given rectally vs. the intranasal route. Absorption of diazepam was more rapid 
in the rectal group when compared to the nasal group subjects.  Target concentrations of 
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> 200 ng/mL were achieved in greater number of subjects in rectal group at the early 
collection times compared to intranasal group. Secondary peaks were evident in the input 
rate profiles of the rectal group but not the intranasal groups.  Although the 
bioavailability of intranasal solution approached 100%, the absorption in the first hour 
following drug administration is slower than rectal administration as noted previously.   
In the current study, we used a dose of 10mg which was administered in one nostril by 
using a 100µL spray.  To achieve a target concentration of 200 ng/mL within an hour or 
even less time, one might have to increase the dose to 20 mg.  This can be easily achieved 
by administering a 100µL spray consisting 10 mg diazepam in both nostrils, but the 
impact of this change in drug administration would need to be investigated.  
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 CHAPTER 4 
 
 
 
 
 
DEVELOPMENT OF INTRAVENOUS BACLOFEN FOR MANAGEMENT OF 
BACLOFEN WITHDRAWAL 
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4.1. A Pilot Study Assessing Pharmacokinetics and Tolerability of Oral and 
Intravenous Baclofen in Healthy Adult Volunteers  
4.1.1 Introduction 
Spasticity is a frequent and prominent symptom of upper motor neuron injury in 
individuals with cerebral palsy, multiple sclerosis, acquired spinal cord injury, brain 
injury and neurodegenerative disorders [115, 146, 147].  In general, spasticity develops 
when an imbalance occurs in the excitatory and inhibitory input to α motor neurons; this 
imbalance is caused by damage to the central nervous system.  Baclofen is a drug used to 
treat spasticity.  It is structurally similar to GABA (gamma aminobutyric acid) and acts as 
a GABAB agonist at the level of the spinal cord [148].  Baclofen is available as oral and 
intrathecal (ITB) formulations. The ITB formulation is used in conjunction with an 
implanted programmable pump to provide a constant infusion of the drug.  Individuals 
treated with oral or ITB may experience a withdrawal syndrome if it is abruptly 
discontinued.  Interruption in ITB therapy may be the result of problems with the 
programmable pump or catheter.  Interruption in oral baclofen therapy may be the result 
of illness resulting in inability to take oral medications, non-compliance, or a scheduled 
surgery for which patients must temporarily stop taking oral medications. This 
withdrawal syndrome can be quite severe, resulting in a rebound increase in muscle tone 
and spasms, status epilepticus, hallucinations, and a neuromalignant syndrome-like 
picture potentially resulting in rhabdomyolysis and multisystem organ failure [114-120] .  
The current recommended management of baclofen withdrawal is inadequate. In the case 
of interruption of ITB therapy, attempts to replace the medication with oral baclofen 
require large doses in an effort to control withdrawal symptoms [116, 121].  Moreover, in 
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spite of using large doses, symptoms are not controlled completely and adverse effects 
including sedation, nausea, vomiting and dizziness may occur.  Diazepam is used by most 
clinicians for its anti-spasticity effect and to decrease the likelihood of acute seizures; 
however, could result in sedation and respiratory depresssion [116, 122].  In conditions 
such as ileus or gastroenteritis, baclofen is not absorbed when given orally and can result 
in baclofen withdrawal.  Use of an intravenous (IV) baclofen formulation could prevent 
or minimize the complications in individuals in whom oral or intrathecal drug delivery is 
interrupted.  Intravenous administration of baclofen would permit rapid attainment of 
drug concentrations as well as accurate and precise dose titration, thus allowing for more 
expeditious treatment of withdrawal symptoms and reduced risk of adverse effects. 
Although oral and intrathecal baclofen have been used for decades, safety and PK studies 
of intravenous baclofen in humans have not been published.  While there are several 
reports of IV baclofen administration in both animals and humans [123-126], details of 
the formulation used in these studies and pharmacokinetic results were not reported.  In 
addition, very limited information was provided about the dose selection and adverse 
events in these studies.  Since an FDA-approved intravenous formulation of baclofen is 
not currently available, a recent clinical study in patients used an extemporaneously 
compounded sterile formulation of baclofen (2.5mg/mL, pH 6.6) to reduce pain from 
muscle spasm and migraines (J Krusz, personal communication 2013).   In the current 
clinical investigation, a commercially available intrathecal formulation of baclofen 
(Lioresal Intrathecal®, 2mg/mL) was used.   
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These circumstances suggest that a FDA-approved commercial IV baclofen product 
would enhance management of patients with spasticity.  The first step in the development 
of such a product is demonstration of its safety in an animal model.  Therefore, a pilot 
study in dogs was conducted to assess the bioavailability, short-term safety, and tolerance 
of intravenous baclofen in comparison to oral administration.  IV baclofen at doses of 0.5 
to 3 mg/kg was well tolerated in dogs [127].  The next phase in the development of an IV 
baclofen formulation would be to conduct a series of investigations in humans.  In the 
current study, safety, tolerability and pharmacokinetics of an intravenous formulation of 
baclofen has been evaluated and compared with oral administration.  The primary 
objective of this study was to characterize baclofen pharmacokinetics after oral and 
intravenous administration in healthy volunteers under fasted conditions in order to 
determine dosing of IV baclofen in subsequent studies.  The other objective of this study 
was to assess the safety and tolerability of a single dose of baclofen given intravenously. 
4.1.2 Methods  
4.1.2.1 Participants 
Twelve healthy adult volunteers gave informed consent and were compensated for 
participation.  Participants who were pregnant or lactating, had a history of sensitivity to 
IV drug administration, or who had a history of significant diseases were excluded from 
the study. All female volunteers involved in the study were post-menopausal for 1 year, 
surgically incapable of bearing children, or were practicing at least one approved method 
of contraception.  The volunteers were medication free for 48 hours before, during, and 
24 hours after the administration of the study drug. The study was approved by the 
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Institutional Review Board of the University of Minnesota and was conducted at PRISM 
Clinical Research Unit (CRU) in St. Paul, MN.  The principal investigator was present at 
the CRU during drug administration. 
4.1.2.2 Study Drugs and Design 
The study utilized a randomized, open-label, two-way crossover design to compare the 
pharmacokinetics and bioavailability of the oral tablet with an intravenous formulation in 
twelve healthy participants. The oral formulation used in this study was a commercially 
available 10 mg tablet (10 mg baclofen,Qualitest Pharmaceuticals). For administering the 
5 mg oral dose in the initial three patients, the tablets were cut in half. A single 
intravenous dose of either 3 or 5 mg was administered over 15 minutes, using the 
commercially available 2 mg/ml intrathecal baclofen formulation (Lioresal Intrathecal®, 
Novartis Pharmaceuticals) that is used in baclofen pumps.   Initially, three participants 
received single 3 mg intravenous and 5 mg oral doses on separate study days with at least 
a 48 hour wash out period between doses. After assessing the safety and clinical tolerance 
of IV baclofen for the three initial participants, an additional nine participants received a 
5 mg intravenous dose and a 10 mg oral dose of baclofen after a washout period of at 
least 2 days.  Blood samples (6mL) for the measurement of plasma concentrations of 
baclofen were collected in blood collection tubes containing K2-EDTA at the following 
times:  prior to dosing and at 5, 15, 30 minutes, and 1, 2, 4, 6, 8, 10, 12, and 24 hours 
after drug administration.   Plasma was separated by centrifugation and stored frozen 
until analysis 
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4.1.2.3 Drug Assay 
Study plasma samples were prepared by adding 50 µL of a 500ng/mL levetiracetam 
solution (internal standard) to 250 µL of K2-EDTA human plasma.  Baclofen and internal 
standard were extracted from plasma by precipitating protein with methanol and dried 
under nitrogen at approximately 40°C.  The dried residues were reconstituted in 300 µL 
of mobile phase consisting of 20 mM ammonium acetate: methanol (75:25) solution.  
After one minute of vortex mixing, reconstituted sample solution was filtered and 
injected onto the HPLC-MS system.  Standard curve samples over a range of 20-400 
ng/mL baclofen and quality control samples containing 30 (low), 80 (medium) and 240 
ng/mL (high) baclofen were prepared and analyzed in triplicate along with the study 
samples.   The assay was linear over the range 20–400 ng/mL with a lower limit of 
quantification of  20 ng/mL. 
4.1.2.4 Data Analysis 
Baclofen concentration–time data were analyzed using a non-compartmental 
pharmacokinetic approach with Phoenix software (version 6.2; Pharsight Corporation, 
Mountain View, CA, USA). The terminal rate constant (λz) was determined from the 
slope of the terminal log-linear portion of the plasma concentration-time curve, and the 
terminal half-life (t1/2) was calculated as ln 2/(λz). Maximum plasma concentrations 
(Cmax) and time to maximum concentration (Tmax) were determined by direct observation 
of the data. The area under the concentration–time curve (AUC) to the last non-
zero plasma concentration (Clast) that was above half the lower limit of quantification 
(10ng/mL) was calculated by the trapezoidal rule and reported as AUClast. The area under 
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the concentration–time curve extrapolated to infinity (AUC0–∞) was calculated as 
AUClast + (Clast/λz).  Mean and standard deviation values for the parameters were also 
obtained using the descriptive statistics tool in Phoenix version 6.2.  A paired t-test was 
used to determine if statistical differences existed in log normalized, dose-adjusted AUC 
between oral and IV arms.  
4.1.2.5 Safety Evaluation 
Safety was assessed by ECG results, blood pressure and pulse monitoring, assessment of 
CNS toxicity, injection site irritation, side effects and tolerability, as well as physical 
exams at 12 and 24 hours after the drug administration.  Ataxia assessment by 
observation of gait was done prior to drug administration, every 30 minutes for the first 4 
hours, and at 12 and 24 hours after the drug administration.  At the same time as ataxia 
assessments, nystagmus and sedation were also assessed.  Nystagmus was assessed both 
at neutral and lateral gaze.  Sedation was assessed using the Stanford Sleepiness Scale 
(SSS) given below [149] : 
1 - Feeling active, vital, alert, or wide awake 
2 - Functioning at high levels, but not at peak; able to concentrate 
3 - Awake, but relaxed; responsive but not fully alert 
4 - Somewhat foggy, let down 
5 - Foggy; losing interest in remaining awake; slowed down 
6 - Sleepy, woozy, fighting sleep; prefer to lie down 
7 - No longer fighting sleep, sleep onset soon; having dream-like thoughts 
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4.1.3 Results 
All 12 subjects (9 male and 3 female) completed the study. The mean (±SD) weight of 
the 12 patients was 79.6 (±13.5) kg. The age range of subjects was 26-56 years, with a 
mean age of 39.3 years. 
A summary of the pharmacokinetic parameters is presented in Table 4.1-1.  A valid 
estimate of λz could not be calculated in subjects receiving the 3 mg IV dose, and thus 
AUC0-∞ and t1/2 were not reported.  This was either due to a coefficient of determination 
(r²) < 0.9000, or an extrapolated AUC that was >30% of AUC0-∞.   The mean 
concentration-time profiles for both (5 mg IV and 10 mg oral) arms are shown in the 
Figure 4.1-1. When the subjects received the intravenous formulation, the observed 
maximum baclofen concentration occurred at the 5 minute time point, whereas, the 
median Tmax for oral administration was 1 hour.  The mean (SD) Cmax values for the oral 
(10 mg) and IV (5 mg) doses were 176 (15) ng/mL and 313 (75) ng/mL, respectively.  
The mean t1/2 was similar for both the oral and IV arms (4 and 4.52 hours, respectively).  
The mean absolute bioavailability of the oral baclofen tablets (Table 4.1-1) was 74 %.  
There was a significant difference in log-normalized, dose-adjusted AUCs (p = 0.0024) 
between oral and IV dosing with similar variability (coefficient of variation: 18-24%). 
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Table 4.1-1. Mean ± SD of baclofen pharmacokinetic parameters following oral (10 
mg) and intravenous (5 mg) administration 
Pharmacokinetic 
Parameter 
5 mg IV 
Mean a ± SD 
10 mg Oral 
Mean ± SD 
Cmax (ng/mL) 310 ± 74 174 ± 16 
Tmax( hr)b - 1.0 [0.5-2.0] 
AUClast  (ng.h/mL) 593 ± 111 878 ± 199 
AUC0-∞  (ng.h/mL) 707 ± 166  1023 ± 232 
AUC0-∞/Dosec  
(ng.h/mL/mg) 141 ± 33 102 ± 23 
Bioavailability (%) - 74± 15 
T1/2 (hr) 4.52 ± 1.6 4.03 ± 0.73 
a: Mean values are presented as arithmetic means 
b: Median (Min, Max) reported for Tmax 
c: Two-tailed p value < 0.05 (Paired t-test performed on dose-normalized AUC) 
 
 
 
 105 
  
Figure 4.1- 1: Mean (±standard deviation) plasma concentration- time profiles of 
baclofen after intravenous and oral administration (0—12 h) 
 
The investigational intravenous formulation was well tolerated.  Most common adverse 
events (AEs) were somnolence, mild ataxia and mild nystagmus.  One subject had mild 
end point nystagmus at baseline and following oral and IV baclofen. Two other subjects 
had mild nystagmus, one after IV and one after oral baclofen.  Mild somnolence (SSS 
score ≤ 4) was observed with both the IV (7 subjects) and oral (3 subjects) doses.  Mild 
ataxia was noted following administration of IV baclofen (4 subjects) and oral baclofen 
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(7 subjects).  All treatment-emergent AEs were characterized by the investigator as being 
mild in severity, and all subjects returned to their baseline values within six hours of drug 
administration.  All subjects were able to normally communicate and walk without 
assistance throughout the entire period of the observation. No AE met the criteria to be 
serious, and none resulted in a subject’s withdrawal from the study. 
4.1.4 Discussion 
To our knowledge this is the first-in-human study investigating intravenous baclofen 
safety and pharmacokinetics in comparison with oral baclofen.  Adverse effects were 
mild in severity and were not related to route of administration.  All subjects in both oral 
and IV groups were awake; however “fogginess” was reported in both groups.  Non-drug 
related factors possibly confounded sedation scores.  For instance, one subject worked the 
night shift prior to a study day and was sleep deprived, which could have resulted in a 
higher sedation score.  All subjects could walk without assistance, although mild ataxia 
was observed in both groups.  However, very low doses were used in this study;  
tolerability at higher clinical doses remains to be established.   
Absolute oral baclofen bioavailability is 74%, indicating that approximately 25% of a 10 
mg dose  is either not absorbed or undergoes first-pass metabolism prior to drug reaching 
systemic circulation.  It also implies that a smaller IV baclofen dose will be needed when 
substituted for oral doses.  For example, assuming linear kinetics, the total systemic 
exposure (AUC) after an intravenous dose of 15 mg would be equivalent to the total 
exposure achieved after 20 mg of oral baclofen dose.  However, the assumption of linear 
pharmacokinetics needs to be evaluated in a dose-escalation study before one can 
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confidently use the 25% reduction to determine the IV dose that results in comparable 
total drug exposure as an oral dose.   One of the key findings of this study was that the 
between subject variability in exposure (AUC) was similar in both IV and oral arms (CV: 
18-24%).  Variability estimates gained from this study will be helpful in determining the 
sample size required for future dose-escalation trials.  
The results of this study indicate that the Cmax observed following IV administration 
would be about four times higher than observed with a similar oral dose.  Generally when 
medications are given IV, a higher Cmax could be a safety and tolerability concern.  
However, in our studies with an animal model, there was no toxicity seen at 0.5 mg/kg IV 
doses (~10-12.5mg) of baclofen in dogs despite Cmax values in the range of 1000 - 1500 
ng/mL.  The dose escalation study in the dogs demonstrated that  higher single doses of 2 
and 3mg/kg (~38-75 mg total dose) eventually resulted in toxicity; but the onset was 
delayed by two to three hours after peak concentrations, which ranged from 4000-7000 
ng/mL [127], further emphasizing the need for a dose escalation study in humans.    The 
disconnect between peak plasma concentrations and drug effects was also demonstrated 
in a mouse model [150].  Moreover, delayed toxicity implies that clinicians might need to 
wait a sufficiently long time period (~2-3 hours) to see the maximum clinical effect of an 
IV baclofen dose in humans as well.   
The results of this study differ somewhat from previously published pharmacokinetic 
studies of oral baclofen given to healthy subjects [91, 92, 151].  Kowalski et al. reported 
an average peak concentration of 540 ng/mL  in eighteen healthy volunteers who 
received a 25 mg dose. [91]. Assuming linear kinetics, a 10 mg oral dose would result in 
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a peak concentration of approximately 215 ng/mL.  However, in the present 
investigation, the average peak concentration was 176 ng/mL following a 10 mg oral 
dose. Average Tmax and half-life reported by Kowalski et al was 2.79 hours and 6.54 
hours respectively, both of which are longer than those herein reported (1  and  ~4 hrs, 
respectively).  Differences in peak concentrations could be due to differences in the 
dissolution or disintegration of tablets,  saturable absorption mechanisms at higher doses, 
assay methodology, or blood sampling times.  
Intravenous baclofen could be useful in several clinical scenarios including prevention or 
treatment of withdrawal from oral or intrathecal baclofen.  One such scenario would be to 
use as a bridge therapy when oral baclofen is discontinued for any reason.   Another 
scenario would use IV baclofen  when ITB therapy is interrupted due to pump failure or 
infection leading to removal of pump.  IV baclofen could also be used to treat baclofen 
withdrawal.  Finding the correct IV doses would be difficult when substituting ITB doses, 
as knowledge of bioavailability is not directly relevant.  Moreover, it has been shown that 
there is no correlation between the intrathecal dosage infused and the corresponding CSF 
baclofen concentration, which further complicates the calculation of therapeutic IV doses 
in managing withdrawal resulting from ITB discontinuation [152].  Designing and 
conducting a study to determine equivalency of IV to ITB dosing would be challenging 
due to both ethical and technical concerns.  For these reasons, studies in appropriate 
animal models may be informative but are lacking. 
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4.1.5 Conclusion 
The PK data gained from this study will guide the design of future trials directed at the 
development of IV baclofen for bridge therapy.  Dose escalation studies are needed to 
assess the safety of higher clinically relevant doses as well as determining the linearity of 
exposure at higher oral doses to aid in correct calculation of replacement IV doses.  Once 
the safety and pharmacokinetics of higher IV doses is demonstrated, dose substitution 
studies in patients on chronic oral baclofen therapy will be necessary to assess multi-dose 
safety and pharmacokinetics.  Lastly, clinicians should be aware of the potential cost of 
IV baclofen therapy.  Nevertheless, in view of the lack of satisfactory alternatives, 
severity of the withdrawal signs and symptoms as well as the possible complications, the 
costs could be justified and would probably be part of inpatient hospital billing. 
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CLINICAL DEVELOPMENT PLAN AND FUTURE DIRECTIONS 
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 5.1 Clinical Development Plan for Intranasal Diazepam for Seizure Emergencies  
There are two possible development paths for the potential approval of a nasal diazepam 
product.  One pathway would be to prove safety and efficacy in one or more well-
controlled clinical trials. The other, possibly quicker, pathway would be to show that the 
nasal product is safe and bioequivalent to the commercially available rectal product.   
The results of the pilot study conducted in healthy volunteers indicate that neither of the 
two intranasal formulations would be bioequivalent to rectal diazepam.  The rate of 
absorption from intranasal formulations was considerably slower than rectal diazepam.  
In addition, there were considerable differences in bioavailability among the three 
formulations.  Although the simulation study showed that in 75% of the trials, the 90% 
confidence intervals of the geometric mean of AUC ratios (IN solution/rectal) fell within 
the bioequivalence limits of 80-125%, the nasal solution failed the bioequivalence test for 
Cmax.  In the absence of pharmacokinetic data demonstrating comparable exposures 
following rectal and intranasal administration, a well-controlled clinical trial to prove 
safety and efficacy in patients would be needed. This chapter outlines the key study 
design elements of an efficacy trial that will be required for the approval of intranasal 
diazepam product and the associated challenges.   
5.1.1 Design of a Safety and Efficacy Trial for Development of Intranasal Diazepam  
Choice of control group 
Recently, Abou-Khalil et al reported the results of a randomized, placebo-controlled study of 
IM diazepam auto-injector for treatment of ARS in which the drug was significantly better 
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than placebo at preventing seizure recurrence [54].  The sample size required for a placebo-
controlled trial will be considerably smaller than that required if a non-inferiority trial is 
conducted using an active-control group.  However, slow patient enrollment is a concern.  In 
addition, a number of measures have to be taken to assure the safety of patients who are 
randomized to placebo group.  In the context of ARS, most of the older children and adult 
patients decline rectal therapy and would agree to enroll in a placebo-controlled trial despite 
knowing that they might get randomized to placebo group.  Pharmaceutical companies prefer 
placebo-controlled trials because they are cost-effective and less time consuming because of 
the smaller sample requirement.   However, a clinician might prefer a non-inferiority trial 
because it provides data for comparative efficacy and safety of investigational drug to that of 
standard of care.  Following below is the study design for a non-inferiority trial comparing IN 
diazepam to rectal diazepam.  In order to appreciate the merits and demerits of active vs. 
placebo control group, an attempt is made to contrast the differences of a non-inferiority trial 
to that of placebo-controlled trial. 
Primary aim  
The primary objective of the study will be to show that the proportion of patients who 
were seizure free in the intranasal diazepam group was not inferior to that in the rectal 
diazepam group by more than a prespecified margin of 10% (the non-inferiority margin). 
Secondary aim 
The secondary objective of this study will be to assess the safety and tolerability of the 
diazepam nasal spray . 
Study design 
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The efficacy trial would be a multicenter, double-blind, double-dummy, parallel, 
randomized, non-inferiority trial comparing the efficacy of intranasal diazepam and rectal 
diazepam.  Diazepam doses for both intranasal and rectal routes would be determined as 
per the Diastat label.   
Procedures  
The Institutional Review Board at each study center will approve the protocol and 
consent procedures and the trial would be conducted under an Investigational New Drug 
(IND) application with the FDA.  Diastat AcuDial syringes with diazepam and placebo 
will be purchased.  Intranasal diazepam spray devices with active ingredient and placebo 
will be obtained from the sponsor.   A Data and Safety Monitoring Committee (DSMC) 
will monitor the study for safety.   
Study population 
Inclusion criteria 
1. Males and females of age 12-45 years with a documented history of ARS.   
2. To ensure timely enrollment, patients need to have at least 4 episodes of ARS 
during the preceding year and at least one episode in the preceding three months. 
3. Patients should be on stable antiepileptic drug dosage regimens for at least 4 
weeks before enrollment. 
4. A cranial CT scan or MRI without evidence of a treatable cause for the seizures. 
5. Females of childbearing potential should have a negative pre-enrollment 
pregnancy test and on-going contraception. 
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6. All patients or their parent or legal guardian should provide assent/written consent 
for study participation. 
Exclusion criteria 
1. Phenobarbital concentrations in plasma >30mg/L. 
2. Current treatment with drugs other than anticonvulsants. 
3. Long term use of benzodiazepines or allergy to diazepam. 
4. Use of CNS depressants or drugs interacting with diazepam. 
5. Patients who had received another investigational medication or device within 30 
days of study entry. 
6. Patients with clinically significant abnormal baseline laboratory values or an 
unstable medical abnormality.   
7. Patients with known history of severe seasonal or non-seasonal allergies, having 
nasal polyps or any nasal passage abnormality that could interfere with nasal spray 
administration. 
Seizure types 
For study purposes, the epileptic seizure type within the episode of ARS could be 
primary generalized, complex partial with or without becoming secondarily generalized, 
or simple partial with a motor component as defined in the International Classification of 
Seizures. (These seizure types are believed to be recognized more accurately by the 
caregiver for counting purposes) [153]. 
Assessments 
 115 
 
Study nurses will train caregivers to identify episodes of ARS, give medication, and 
record in a study booklet respiration, skin, color, seizures, adverse events, and global 
assessment of treatment outcome.  During episodes of ARS, study nurses will maintain 
telephone contact with the caregivers to review procedures, monitor patients, and 
intervene as necessary if patients need additional treatment.  The observation period will 
begin 15 minutes after the first dose and will continue up to 12 hours.  The patients and 
care givers will be scheduled to return to the clinic 72 hours after treatment to review the 
recorded data. 
Sample size and power calculation   
Published studies of similar patient populations show that 60% of subjects were seizure 
free when treated with rectal diazepam [153].  Sample size was determined to have 90% 
power to show the non-inferiority of intranasal diazepam with a margin of 10% using a 
one-sided test with the probability of a type I error of 0.025.  The placebo-controlled trial 
conducted by Abou-Khalil et al calculated a sample size of 86 patients per group for 90% 
power [54].  In contrast, for the non-inferiority trial, sample size required for 
randomization is 722 patients per treatment group, assuming 70% of the patients 
randomized will be treated.  Some patients, though enrolled, may not actually be treated 
due to several reasons.  These include withdrawal of consent before treatment, and some 
may become ineligible post-enrollment.  Practical issues such as  absence of a caregiver, 
need of other concomitant medications, lost to follow-up, improper dosing, and 
incomplete data recording are some other factors to inflate the sample size.  Assuming 
average enrollment rate of 6 patients per clinic per year with 50 participating centers, 
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patient enrollment will take place for 5 years for the non-inferiority trial.  In contrast, the 
placebo-controlled trial, which would require enrollment of about 300 patients, can be 
completed in less than 2 years.  
In addition to the 5 years of enrollment, factoring in the time for study start-up and end-
of-study procedures, it will take 7 years to complete the non-inferiority trial.  Though a 
non-inferiority trial provides comparative efficacy data, it will take a long time and 
require a large study.  Therefore, a placebo-controlled trial would be feasible as it is less 
time consuming and cost effective. 
Statistical analysis 
All patients who receive study medication will be included in the analysis.  Demographic 
and baseline variables such as sex, age, age group (6-12 and >12-17 years), race, weight, 
seizure etiology, ARS frequency, and seizure type (complex partial vs. generalized) will 
be analyzed for comparability between rectal and intranasal diazepam treated groups.  
Categorical variables will be analyzed using chi-square test.  If any of the expected 
subgroups are less than 5 then Fisher’s Exact Test will be used.  Baseline values of age 
and weight are analyzed with a two-sample t test.  ARS frequency at baseline will be 
analyzed with a Wilcoxon rank-sum test because literature review indicates that such data 
are not normally distributed. 
The primary objective of the study is to show that the proportion of patients who were 
seizure free during the observation period of 12 hours in the intranasal diazepam group 
was not inferior to that in the rectal diazepam group by more than a prespecified amount 
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(the non-inferiority margin).  The null hypothesis of inferiority will be tested with one-
sided z statistic [3].  The secondary efficacy variable (seizure count) for the two treatment 
groups (Diastat versus Intranasal diazepam) will be compared using Wilcoxon’s rank 
sum test at 0.05 significance level. 
Primary efficacy analysis/Significance testing 
If the one-sided 97.5% CI (or equivalently the two-sided 95% CI) of the absolute 
difference of two treatments (Δ = PIN – Prectal) excludes -0.1 (-10%), then we show that 
intranasal diazepam is non-inferior.   
Challenges to physician and patient cooperation 
Designing and conducting a study to demonstrate safety and efficacy would be challenging.  
Clinical staff training, time to explain the study to patients, follow-up burden etc. are 
some likely challenges to physician participation.  To overcome this challenge, the study 
design should be simple, data collection forms should be user friendly and not 
cumbersome.  Patient’s willingness to participate in research is one of the most common 
challenges in clinical research.  Another challenge is the availability/willingness of 
caregiver to record the events, which is essential for proper study execution.  Subjects 
who are already stable on rectal product might be interested in trying an intranasal 
product, but the need to fill out data collection forms might be a hindering factor for 
patient enrollment.   
An Alternate Apporach to Study Design: Bayesian adaptive methods 
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One can employ Bayesian adaptive methods to address the large sample size 
requirements of a non-inferiority trial.  Bayesian methods allow use of historical data and 
interim trial results to modify study design adaptively to reduce both time and expense.  
Bayesian adaptive designs allow for unlimited looks at accumulating data because of its 
different framework for testing, which will allow stopping a trial sooner.  From a 
frequentist view, one cannot take a look at accumulating data unless the trial is completed 
or an interim analysis is planned.  Bayesian methods are different in that you can take 
multiple looks and make decisions early if a particular arm is performing better than what 
was expected during the sample size calculations.   If we have more than one 
investigational treatment in a trial, Bayesian methods will allow you to drop an 
unproductive or unpromising treatment, without completing the whole trial as initially 
planned.  Bayesian adaptive methods will also allow the assignment of more patients to a 
more promising arm.  For example, if a particular intranasal formulation is performing 
better than another formulation, adaptivity will allow more patients to get randomized to 
that particular formulation.  In summary,  frequentist statistical inference for hypothesis 
testing is design-based; if you change the design of the experiment, you change the 
reference set of outcomes, and thus the p-value.  Therefore, you cannot change the study 
design when employing frequentist methods.  However, Bayesian approach allows more 
flexibility as inference is model-based and does not use p-values.  The non-inferiority 
study described here uses frequentist approach and an interim analysis is not planned 
given that it will inflate the already large sample size further and a Bayesian approach 
would be preferable in this case for the reasons outlined above.  
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 5.2 Development of Intravenous Baclofen for Prevention of Baclofen Withdrawal 
We are encouraged by the experience gained with the series of investigations with regard 
to developing an IV formulation of baclofen.  Bolus doses and continuous infusions of IV 
baclofen were tolerated by dogs without instability of vital signs at doses much higher 
than those typically used in humans with oral baclofen. The results of current research in 
humans described in this thesis showed that 3 and 5 mg of baclofen doses given IV are 
well-tolerated by healthy adults.  Future studies in humans are being planned to 
investigate the pharmacokinetics and safety of escalating single doses of intravenous 
baclofen, as well as the optimal approach to substituting intravenous baclofen 
administration when oral or intrathecal baclofen therapy is interrupted.  Figure 5.2-1 lists 
a number of studies which we envision to be required for the commercial development 
and marketing approval of IV baclofen. The first two studies in Figure 5.2-1 are 
completed and Study III is in planning stage.   
 
Figure 5.2- 1: Clinical Studies Required for Commercial Development of IV 
Baclofen 
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5.2.1 Designing Phase 1 Dose-escalation Study of Intravenous Baclofen in Healthy 
Subjects (Study III) 
Objectives  
1) Determine the safety profile of commonly used doses of baclofen when given 
orally and intravenously. 
2) Characterize baclofen pharmacokinetics of escalating doses after oral and 
intravenous administration in healthy adults. 
3) Determine oral bioavailability and assess dose-proportionality of single doses of 
10, 15 and 20 mg of oral and 7.5, 11.5, 15 mg of intravenous baclofen, 
respectively. 
Study Design 
This study will utilize a randomized, open-label, three phase, two-way crossover design 
to compare the pharmacokinetics and bioavailability of the oral tablet with an intravenous 
formulation in thirty six healthy participants.      
Dosing Scheme 
Phase one: Twelve subjects will be randomized to receive 10 mg doses of oral and 7.5 
mg of IV baclofen in a crossover fashion; 3 of these subjects will receive the 7.5 mg IV 
dose initially to evaluate safety and tolerance.  If these 3 subjects tolerate the IV dose, the 
remaining 9 subjects at this dosing level will be randomized to receive either oral or IV 
dose first.  
Phase two: If 7.5 mg intravenous dose of baclofen is tolerated by all subjects, then 12 
different subjects will receive 15 mg baclofen orally and 11.5 mg baclofen intravenously; 
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3 of these subjects will receive the 11.5 mg IV dose initially to evaluate safety and 
tolerance.  If these 3 subjects tolerate the IV dose, the remaining 9 subjects at this dosing 
level will be randomized to receive either oral or IV dose first.  
Phase three: If 11.5 mg intravenous dose is tolerated by all subjects, then 12 different 
subjects will receive 20 mg baclofen orally and 15 mg baclofen intravenously; 3 of these 
subjects will receive the 15 mg IV dose initially to evaluate safety and tolerance. If these 
3 subjects tolerate the IV dose, the remaining 9 subjects at this dosing level will be 
randomized to receive either oral or IV dose first. 
Dose Justification 
In this dose-escalation study, single oral doses of 10, 15 and 20 mg baclofen, which are 
commonly used clinically will be studied.  Since the first-in-human study results 
demonstrated that the oral bioavailability of baclofen was 74%, equivalent IV doses (75% 
of oral doses) of 7.5, 11.5 and 15 mg will be studied. 
PK Sample Collection 
Blood samples (6mL) for the measurement of plasma concentrations of baclofen will be 
collected in blood collection tubes containing K2-EDTA at the following times:  prior to 
dosing and at 5, 15, 30 minutes, and 1, 2, 4, 6, 8, 10, 12, and 24 hours after drug 
administration.   Plasma will be separated by centrifugation and stored frozen until analysis 
Safety Assessments 
Safety will be assessed by ECG results, blood pressure and pulse monitoring, assessment 
of CNS toxicity, injection site irritation, side effects and tolerability, as well as physical 
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exams at 12 and 24 hours after the drug administration.  Ataxia assessment by 
observation of gait will be done prior to drug administration, every 30 minutes for the 
first 4 hours, and at 12 and 24 hours after the drug administration.  At the same time as 
ataxia assessments, nystagmus and sedation will be assessed.  Nystagmus will be 
assessed both at neutral and lateral gaze.  Sedation will be assessed using the modified 
Stanford Sleepiness Scale (SSS) given below: 
1 - Feeling active, vital, alert, or wide awake 
2 - Functioning at high levels, but not at peak; able to concentrate 
3 - Awake, but relaxed; responsive but not fully alert 
4 - Somewhat foggy, let down 
5 - Foggy; losing interest in remaining awake; slowed down 
6 - Sleepy, woozy, fighting sleep; prefer to lie down 
7 - No longer fighting sleep, sleep onset soon; having dream-like thoughts 
8- Asleep, unable to awaken 
Study Stopping Rules 
If any subject develops severe ataxia (unable to walk without assistance) or is observed to 
have a sleepiness scale of 8, no further dose escalation will occur. In addition if an SAE 
occurs in any participant we will ask the Medical Monitor to determine whether the 
adverse event was due to study medication.  If it is deemed due to study medication no 
further subjects will be given IV baclofen. 
Data Analysis 
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Descriptive statistics will be used to summarize the data from this study.  In addition to 
standard pharmacokinetic analysis to calculate absolute oral bioavailability, statistical 
analysis of dose-normalized PK variables Cmax, AUClast and AUC0-∞ will be done 
after log transformation.  Dose proportionality will be assessed by ANOVA followed by 
Tukey’s multiple comparison tests to detect statistical differences in AUC and Cmax 
among the oral and IV doses.   
5.2.2 Dose Substitution Studies of IV Baclofen in Patients under Steady-State 
Conditions (Study IV and V) 
Once the safety of escalating doses is established in healthy volunteers, the next step is to 
conduct dose substitution studies in patients chronically receiving baclofen.  Based on the 
absolute oral bioavailability estimate obtained from studies in healthy volunteers, oral 
doses of baclofen in patients can be substituted with an equivalent IV dose.  However, 
one needs to note that these patients are under steady-state conditions and characterizing 
the absolute bioavailability can be done using an IV formulation of stable-labeled isotope 
of baclofen.  In this study a portion of the patient’s usual oral dose will be replaced and 
co-administered with an intravenous stable isotope of baclofen.  This approach permits 
measurement of the absolute bioavailability, clearance, distribution volume, and 
elimination half-life parameters that cannot usually be determined from only oral dosing 
studies.   For drugs such as baclofen where discontinuation of therapy is not possible, 
stable-labeled (nonradioactive) isotopes followed by mass spectrometry analysis can be 
used to characterize pharmacokinetics in patients under steady-state conditions.  
For faster approval of IV baclofen and in absence of data suggesting that spasticity alters 
bioavailability of oral baclofen, one can argue that a single dose substitution study (study 
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IV) is not required in patients.  One can make an assumption that oral bioavailability in 
healthy adults and patients would be similar.  This would then allow to directly conduct a 
safety and PK study following multiple doses of IV and oral baclofen. 
5.2.3 Application of Modeling and Simulation to Optimize IV Dosing Regimen  
When oral baclofen therapy is interrupted, similar total exposures can be attained by 
initiating IV therapy using equivalent doses based on the absolute bioavailability 
estimates obtained from the PK studies outlined above.  However, the dosing regimen 
may have to be modified.  IV doses given using the same dosing regimen as the oral 
therapy will result in higher peak and lower trough concentrations than those seen from 
oral administration.  It will be necessary to modify the dosing regimen by decreasing the 
dose and increasing the dosing frequency to achieve similar peak and trough 
concentrations.  A PK model developed with the data obtained from the studies outlined 
above could be used to simulate concentrations from several dosing regimens.  These 
simulations could provide helpful information in optimizing IV baclofen dosing regimen to 
maintain target drug concentrations within desired therapeutic window.  The same PK model 
can also be used to optimize other dosing regimens such as intravenous infusions of varying 
dose rates if precise concentrations are to be maintained. 
On the other hand, calculating IV doses for preventing or treating baclofen withdrawal 
resulting from interruption of intrathecal therapy is not straightforward.  Daily intrathecal 
baclofen doses are typically very low and a study analyzing 43 patients (28 males, 15 
females; range 3-44years) reported a range of 70 to 1395 mcg/day (median 575 
mcg/day)[152].  When given intrathecally, the drug is delivered near the site of action; there 
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is minimal enzymatic degradation; restricted distribution to supraspinal tissues explaining the 
reason for smaller ITB doses required to treat spasticity.  One paradigm to calculate required 
IV doses would be to dose patients with an aim to achieve same cerebrospinal fluid (CSF) 
baclofen levels as those achieved after intrathecal baclofen delivery.  However, in clinical 
practice CSF levels are rarely available.  In the absence of CSF levels, the soleus H-reﬂex can 
be used to guide the IV dosing of baclofen.  The soleus H-reflex measure provides an 
objective, reproducible, and sensitive index of changes in spinal excitability and future 
clinical trials of baclofen should explore its potential use.   
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CONCLUSIONS 
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CONCLUSIONS 
The overall goal of this project was to characterize the pharmacokinetics, bioavailability 
and tolerability of CNS drugs used in the acute treatment of seizure emergencies and 
spasticity.  Two drugs were studied: diazepam and baclofen.  Both of these drugs are 
already approved by the FDA and have been extensively used.  In the case of baclofen, 
commercially available intrathecal baclofen solution was administered intravenously to 
characterize its pharmacokinetics and safety in humans. 
For diazepam, the pharmacokinetics and tolerability of two novel formulations were 
evaluated for intranasal delivery as rescue therapy in seizure emergencies. While rectal 
diazepam (Diastat Acudial™) is safe and effective in treating ARS, its use is limited 
because of patient/family/teacher objections to the route of administration, particularly 
when the drug needs to be administered at work, school, classroom, or public locations.  
Furthermore, systemic exposure following rectal administration is widely variable given 
the potential for bowel movements or other factors that impact absorption of drugs.  The 
availability of an intranasal diazepam product that is easily and safely administered and 
rapidly and completely absorbed would add significant clinical benefit to patients who 
experience ARS.  The results of earlier studies by our research group concluded that 
intranasal diazepam offers a viable alternative to rectal administration, however further 
enhancement of formulations was needed both to improve tolerability and the extent and 
consistency of absorption.  In the current work, two novel formulations of diazepam nasal 
spray were evaluated and compared with intravenous diazepam administration in a phase I 
pilot PK study.  Of the two formulations that were tested, namely, nasal suspension and nasal 
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solution, the absolute bioavailability of the latter approached ~100% and this formulation was 
well tolerated with no reports of nasal pain or irritation. Therefore, this formulation has the 
potential to serve as an alternative mode of therapy to rectal diazepam and is preferred 
candidate  for further development.  Additional clinical trials including dose-escalation, and 
safety and efficacy studies in patients are required before market approval.   
For baclofen withdrawal, the current recommended management strategies are inadequate 
and availability of intravenous baclofen would permit rapid attainment of drug concentrations 
in plasma as well as accurate and precise dose titration, thus allowing for prevention and 
expeditious treatment of withdrawal symptoms and reduced risk of adverse effects.  In the 
current work described in this thesis, a commercially available intrathecal formulation of 
baclofen was administered intravenously to evaluate and compare with oral baclofen tablets 
in a phase I pilot PK study.  The absolute bioavailability of the oral tablets was found to be 
74 % and the small doses of baclofen given IV were well tolerated.   The PK data gained 
from this study will guide the design of future trials directed at the development of IV 
baclofen for bridge therapy.  Dose escalation studies are needed to assess the safety of higher 
clinically relevant doses as well as for determining the linearity of exposure at higher oral 
doses to aid in correct calculation of replacement IV doses.  Once the safety and 
pharmacokinetics of higher IV doses is demonstrated, dose substitution studies in patients on 
chronic oral baclofen therapy will be necessary to assess multi-dose safety and 
pharmacokinetics.   
In conclusion, the research described in this thesis suggests that both intranasal diazepam and 
intravenous baclofen hold promise in management of seizure emergencies and baclofen 
withdrawal, respectively. 
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 APPENDIX 
 
NONMEM Code for PK Model 
$PROB RUN# 201 
$INPUT ID TIME AMT DV EVID CMT OID=DROP TRT FORM STDY PERI DLVL 
AGE SEX RACE WT TAD 
$DATA IVPRINDZP.CSV IGNORE=@ 
$SUBROUTINES ADVAN4 TRANS4 
$PK 
TVCL=THETA(1) 
CL=TVCL*EXP(ETA(1)) 
TVV2=THETA(2) 
V2=TVV2*EXP(ETA(2)) 
TVQ=THETA(3) 
Q=TVQ*EXP(ETA(3)) 
TVV3=THETA(4) 
V3=TVV3*EXP(ETA(4)) 
 
KAPR=THETA(5)*EXP(ETA(5)) 
F1PR=THETA(6)+ETA(6) 
 
KASUSP=THETA(7)*EXP(ETA(7)) 
F1SUSP=THETA(8)+ETA(8) 
 
KASOL=THETA(9)*EXP(ETA(9)) 
F1SOL=THETA(10)+ETA(10) 
 
DUM6=0 
IF(FORM.EQ.6) DUM6=1 
DUM7=0 
IF(FORM.EQ.7) DUM7=1 
DUM8=0 
IF(FORM.EQ.8) DUM8=1 
KA=DUM6*KAPR+DUM7*KASUSP+DUM8*KASOL 
F1=DUM6*F1PR+DUM7*F1SUSP+DUM8*F1SOL 
 
SC=V2/1000 
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$ERROR 
Y = F + F*ERR(1) 
IPRED=F 
IRES=DV-IPRED 
W=IPRED 
IWRES=IRES/W 
 
$EST METHOD=1 INTERACTION PRINT=5 MAX=9999 SIG=3 MSFO=40001.MSF 
NOABORT 
$THETA  
(0, 1);CL 
(0, 20);V2 
(0, 10);Q 
(0, 60);V3 
(0, 1);KAPR 
(0,.8,1);FPR 
(0, 1);KAINSUSP 
(0,.8,1);FINSUSP 
(0, 1);KAINSOL 
(0,.8,1);FINSOL 
 
$OMEGA 
0.1 ;  CL 
0.1 ;    V2 
0.1 ;      Q 
0.1 ;      V3 
0.2 ; KAPR 
0.005 ;FPR 
0.2 ; KAINSUSP 
0.005 ;FINSUSP 
0.2 ; KAINSOL 
0.005 ;FINSOL 
 
$SIGMA 
0.01 
 
$TABLE ID TIME IPRED CWRES TAD IWRES ONEHEADER NOPRINT 
FILE=sdtab001 
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$TABLE ID ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 ETA9 ETA10 CL V2 
Q V3 KA F1 NOAPPEND NOPRINT FILE=patab001 
 
$TABLE ID AGE WT FIRSTONLY NOAPPEND NOPRINT FILE=cotab001 
$TABLE ID SEX RACE FORM FIRSTONLY NOAPPEND NOPRINT FILE=catab001 
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